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Significant effort has been spent on altering the pharmacokinetic profile of drugs 
and identifying ways to slow down the GI transit of the therapeutic, especially that of the 
small intestine, the location where the majority of absorption occurs.  The two main areas 
of thrust for research pertaining to increasing the bioavailability of drugs possessing 
narrow absorption windows are retaining the dosage form in the stomach 
(gastroretentive) and slowing down transit time in the small intestine (mucoadhesive).  
Gastroretentive dosage forms maintain the drug delivery system above the absorption 
window and release the drug accordingly.  Mucoadhesion affords the ability to slow 
upper GI transit by maintaining the dosage form at the site of absorption through some 
type of interaction with the intestinal mucosa.  The motility of the gastrointestinal tract 
plays a major role in appropriately engineering a dosage form.  The delivery system must 
be designed so that it works with the digestive system to accomplish the goal of targeting 
 viii
the area where the narrow absorption window of the therapeutic exists and controlling the 
release to enhance the pharmacokinetic profile.  
Smart biomaterials composed of pH responsive polymers, poly((meth)acrylic 
acid), were synthesized using a precipitation polymerization technique.  The 
microparticles were grafted with linear polymer chains (PEG) that are capable of 
complexing with the hydroxyl groups of the polyacid and interpenetrating into the mucus 
gel layer upon entry into the small intestine.  Upon introduction of an alkaline solution, 
these materials imbibe a significant amount of water and create a highly viscous solution.  
The gelled materials serve as both a controlled release membrane and resist the inertial 
forces associated with motility, thereby effectively slowing down the transit of the dosage 
form.  The amount and length of the linear chain were varied to investigate their effects 
on the release behavior of a model compound.   
 ix
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Figure A.21:   In (A) 3D projection a micropatterned square array of a biomimetic 
polymer network based on a crosslinked polyacrylamide obtained 
utilizing a confocal microscope.  In (B) a slice of the square array is 
demonstrated. ..................................................................................212 
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 Chapter 1:  Introduction 
The oral delivery of small molecular weight drugs, macromolecules, and vaccines 
remains the most favored route of administration.  However, barriers exist in successfully 
administering drugs via the gastrointestinal tract and achieving a predictable and 
increased oral bioavailability.  These barriers include but are not limited to a mucous gel 
layer lining the gastrointestinal epithelia, a degradative pH that varies from patient to 
patient, a relatively short transit time past the ideal absorption sites, and a system of 
degradative enzymes (Figure 1.1). 
For small molecular weight drugs (500-700 Daltons), the narrow absorption 
window of the proximal intestine poses the greatest challenge in the development of a 
modified or controlled release product (1).  Drugs that are transported across the small 
intestine through some form of facilitated transport or polar compounds are readily 
absorbed in the proximal gut; however the molecules exhibit very low absorption in the 
distal gut (or colon).  The relatively short period of transit (3 h for the small intestine and 
as much as 20 h for the colon), and, in effect, absorption, can significantly affect the 
drug’s oral bioavailability, necessitating a need for a prolonged residence time at the 
large absorptive surface area of the small intestine. 
The successful oral delivery of macromolecules faces major challenges which are 
a result of their much larger size (> 500-700 Da), hydrophilicity, vulnerability to 
proteolytic degradation, and narrow window of effective absorption, all of which have 
limited their commercial and clinical development (2).  Drug carriers have shown great 
promise in enabling the successful delivery of proteins and peptides by overcoming the 
aforementioned challenges without modifying the structure of the macromolecular 
therapeutic, damaging epithelial membranes, or creating new toxicities (3-7).  However, 
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rapid transit of the drug carrier past the ideal site of absorption still poses a challenge in 
developing an effective and efficient oral macromolecular drug delivery system (8).  
Two phenomena have been used to solve the problem of rapid transit of a 
therapeutic past the location of maximal absorption:  gastroretention and bioadhesion.  
Both areas address the need for controlling the spatial location of an oral drug delivery 
system to achieve a maximal bioavailability.  Gastroretentive dosage forms provide a 
system that maintains the drug above the compound’s window of absorption, releasing 
the therapeutic slowly so that the time available for the body to effectively absorb the 
pharmaceutical ingredient is increased (9). Since the early 1980s, the phenomenon of 
bioadhesion has offered promise in enabling the development of drug delivery carriers 
and systems that are capable of an increased residence time in the narrow absorption 
window of the drug.  Bioadhesion, or more specifically mucoadhesion, is defined as the 
attachment of a biological or synthetic moiety to a biological substrate such as the 
mucous gel layer lining the oral cavities of the body. 
Mucoadhesive oral drug delivery systems allow for intimate contact to develop 
between the system and the ideal absorption site (most cases, the small intestine), which 
aids in maximizing the rate and extent to which a drug absorbs.  Major adversities 
encountered in designing superior mucoadhesive systems include the motility of the 
digestive tract which is designed to move contents, the rate of mucus turnover and the 
amount of sloughed or free mucous gel that resides in the lumenal environment.   
A mucoadhesive is the synthetic or semi-natural material, most commonly a 
polymer, which is responsible for the interaction between the drug carrier and the mucous 
gel layer.  Recent advances in mucoadhesives include polymer networks that contain 
thiolated moieties available for disulfide bond formation with mucin molecules (10), 
polymer tethers capable of interpenetrating the mucous gel layer to create a bridge 
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between the system and the mucous gel layer (11, 12), and mucin recognitive molecules 
(or their carbohydrate side-chains) such as lectins (13, 14), fimbrial proteins (15), and 
chitosan (16-18).  These advances offer promise in that the technology is advancing and 
systems are evolving to become more effective.  However, there is much knowledge to be 
gained in order for biomimetic systems to be developed that offer characteristics 
representative of biological mucoadhesive organisms, namely the bacteria comprising the 
intestinal microflora (19-21).  
The surface of the polymeric drug delivery carrier remains the integral part in 
obtaining a mucoadhesive interaction with the mucous gel layer, as it is this surface that 
is at the interface with the mucosal lining.  A surface layer of polymer has been shown to 
have the capacity to act as an adhesion promoter in developing intimate contact between 
the carrier and the mucosal lining (22).   
The purpose of this work is to combine the theoretical framework developed for 
polymer tethers as adhesion promoters with a drug delivery system capable of achieving 
a controlled or modified release of a model compound.  The objective is the design and 
evaluation of an oral mucoadhesive drug delivery that would be capable of spatially 
controlled release.  Also, the molecular characteristics of the tethered polymers will be 
evaluated to determine their effects on mediating adhesion. 
The research objectives and focus of this dissertation are presented in Chapter 3 in 
greater detail.  Chapter 4 investigates the synthesis and characterization of lightly 
crosslinked microparticles composed of poly(acrylic acid) or poly(methacrylic acid) 
prepared using a free radical precipitation polymerization.  Chapter 5 evaluates the 
dynamics of poly(acrylic acid) and poly(methacrylic acid) hydrogel microparticles 
containing poly(ethylene glycol) (PEG) tethers of varying molecular weights.  Chapter 6 
elucidates on the drug release behavior of polymer-containing matrices.  The fundamental 
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properties of the polymer, such as amount of crosslinking agent incorporated, type of pH 
responsive monomer employed, pH of drug release media, amount of poly(ethylene 
glycol) (PEG) tether, and molecular weight of PEG tether, are controlled to analyze their 
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(<500-700 Da) Macromolecules 
• Compounds having low 
permeability (III) or 
solubility (II) or both (IV) 
can have a significant impact 
on the oral bioavailability 
• Molecules transported via 
facilitated transport are not 
absorbed in various regions 
of the GI 
 
• Drugs have a short transit 
time past ideal absorption 
site which is most commonly 
the small intestine 
 
• Proteins are hydrophilic and 
do not possess the 
lipophilicity needed for 
passive transport 
• The large molecular mass 
eliminates the paracellular 
route for transport 
• Proteolytic degradation by 
enzymes located in the 
stomach renders the drug 
inactive 
• Macromolecules have a short 
transit time past the ideal 
absorption site of the small 
intestine 
 
Figure 1.1 Physiological challenges encountered in both the development of modified 
or controlled release oral dosage forms for low molecular weight 
compounds and the effective delivery of macromolecules. 
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Chapter 2:  Background 
BIOADHESION 
Adhesion refers to the molecular contact (adherence) of two substances, which 
typically involves the application of an adhesive between these two entities (Figure 2.1).  
Historically, adhesives (1) and bioadhesives have been used as terms in two distinctly 
different areas of thought with very little overlap and continuity.  The term adhesive, or 
biological adhesive, has been used to describe a particular biomaterial or system that is 
responsible for adherence.  Bioadhesion has largely remained well entrained in the field 
of biology referring to cellular interactions (cytoadhesion) or to mucosal adhesion 
(mucoadhesion).   
Whether it is cell-to-cell, soft or hard tissue, or mucosal adhesion, bioadhesion is 
the phenomenon of long term contact of a synthetic or biological macromolecule or 
hydrocolloid with a biological substrate (2-7).  Therefore, bioadhesion can be extended to 
include any type of adhesion process in contact with or within the biological milieu.  The 
term bioadhesive refers to the particular substance, natural or synthetic, responsible for 
this adhesion.  Surfaces usually employed in bioadhesive applications involve synthetic, 
natural, or hybrid macromolecules, which can be found on biological components such as 
cells composing tissue and blood platelets.  Mucoadhesion is often used to describe 
bioadhesion where mucus is the substrate, whereas cytoadhesion refers to cell-to-cell 
bioadhesion. 
The substrate to which bioadhesion occurs is quite different in its physical 
properties than those employed in conventional adhesion.  Soft tissue or a synthetic 
material is often used to adhere another soft tissue.  Bioadhesives have found success in 
hard tissue applications such as orthopedics and dentistry due to the relatively more 
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favorable biological environment presented in these areas (8).  Recently there has been 
significant interest in the development of more effective bioadhesives for tissue 
engineering (9-11) and carriers for drug delivery (2-7) applications, both areas in which 
clinical success has not been as successful.  Also, the understanding of bacterial adhesion 
has received considerable attention to further the knowledge behind biofouling (bioflim 
formation) and the role bacterial bioadhesives play.   
THEORETICAL AND MECHANISTIC ASPECTS OF BIOADHESION 
The mechanisms that describe the phenomena of bioadhesion and the structural 
characteristics of bioadhesives were originally proposed by Peppas and Buri (5). The 
components of importance for obtaining adhesion are the surface containing the 
bioadhesive, the surface of the biological substrate, and the interface between these two.  
The bioadhesive must come into intimate contact with the substrate (either with an 
external applied force, through an attractive force, or by collision).  For liquid 
bioadhesive formulations, the bioadhesive fills the inclusions provided by the surface 
roughness and develops a physical or mechanical bond, which is quite common in 
orthopedic or dental applications.  Once contact has been achieved, the macromolecules 
responsible for the adhesive characteristics are then able to interact with specific moieties 
present on the substrate’s surface.   In some instances, due to the high mobility of the 
surface macromolecules, interdiffusion occurs and the interdigitated macromolecules are 
capable of interacting with other moieties present on the subsurface or entangling with 
other macromolecules composing the surface of the substrate to develop a bioadhesive 
bond.  The molecule to molecule bioadhesion is attributed to bonding derived from either 
covalent or noncovalent interactions.   
Primary chemical interactions occur through ionic bonding, disulfide bonds, or a 
chemical reaction between the functional groups of the adhesive and the substrate.  
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Secondary chemical interactions are attributed to electrostatic forces (ionic and dipole-
dipole, Figure 2.2), hydrogen bonding, or hydrophobic forces.  The theories that describe 
the chemical mechanisms include the electronic theory and the adsorption theory, and 
those that describe the physical mechanisms include the wetting theory, the 
interpenetration or diffusion theory, and the fracture theory (2, 4, 5).   
The electronic theory describes adhesion in terms of the differences in the 
electronic structures of the materials involved.  After the materials come into contact, a 
double layer of charge forms at the interface, and adhesion occurs due to these attractive 
forces (12).  The adsorption theory describes materials that adhere to mucus due to 
secondary forces such as van der Waals, hydrogen bonding, or hydrophobic interactions 
(13, 14).  Due to the presence of a large number of these types of forces, the net force is 
greater than that which is created by electrostatic forces.  The wetting theory describes 
the ability of a mucoadhesive to spread over the mucus gel layer and develop an intimate 
contact (15-17).  The parameters used to correlate a materials mucoadhesive capacity 
based upon this theory are the individual materials’ spreading coefficients which aid in 
calculating the interfacial energy.  The diffusion theory describes mucoadhesion as a 
process where the chains of the materials interpenetrate to a sufficient depth to create a 
semipermanent bond (18, 19).   
Each individual theory fails to sufficiently describe the phenomenon of 
bioadhesion; therefore, combining various aspects of the theories enables a more 
appropriate description (20).  As a bioadhesive approaches the biological substrate, it 
reaches equilibrium with the biological environment, which can include wetting and 
swelling.  As the material comes into contact with the biological substrate, non-covalent 
secondary bonds are formed at the bioadhesive-substrate interface through either non-
specific or specific interactions.  As the bioadhesive continues to reside in contact with 
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the substrate, macromolecules of the respective materials interdiffuse into one another 
while forming more and more noncovalent bonds.   
The field of bioadhesion is receiving a great deal of attention in a wide variety of 
fields related to biomedical engineering.  These main areas of thrust are discussed along 
with the current research efforts. 
DRUG DELIVERY 
Drug delivery applications utilize bioadhesive macromolecules to localize 
treatment to a specific area of the body, thereby increasing the residence time of the 
therapeutic and improving the oral bioavailability (21-23).  For intravascular applications, 
a targeting agent such as a ligand is incorporated into the drug delivery system, creating 
adhesion through the ligand-receptor interaction present at the endothelium surface.  
Bioadhesion in this instance is governed by (i) the shear stress caused by the 
hemodynamic force exterted over the cell/particle, the loading rate which is affected by 
the viscosity of the biological environment, and the ligand/receptor density ratio which 
can be controlled during the fabrication of the system (24).  For oral drug delivery 
systems, mucoadhesion is the specific type of bioadhesion responsible for localizing the 
system at the mucous gel layer, which lines the absorptive regions of the alimentary 
canal. 
Mucoadhesive polymer-based drug delivery systems were first utilized by Nagai 
and collaborators as carriers for local treatment to the buccal cavity (25, 26).  Mucus is 
also present in the nasal and gastrointestinal cavity, the vagina, and other hollow organs, 
providing a diverse arena for the application of mucoadhesive drug delivery systems. 
Polymers that have typically been utilized in the development of mucoadhesive 
controlled release formulations include hydrophilic macromolecules containing numerous 
hydrogen bonding groups such as poly((meth)acrylic acid) which include the carbomer 
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and polycarbophil families (Figure 2.3), cellulosics, and (semi)natural ones such as 
chitosan and alginate (27).  Like so many other materials that were first utilized in 
biomedical applications (cellulous acetate dialysis tubing, Dacron® vascular grafts, and 
polyurethane heart molds), these materials were available off-the-shelf.  Because their 
use was originally intended for other applications and was only transitioned into oral drug 
delivery systems, the drug delivery systems comprised of these materials have been 
classified as the first generation bioadhesive-based dosage forms (4).   
Dosage forms have been engineered so that they take advantage of the abilities to 
molecularly design polymer networks to impart specific structural characteristics so that 
polymers comprising the dosage form are multifunctional.  This new generation of 
bioadhesives has employed hybrid materials such as lectins, fimbrial proteins, or ligands 
which have specific interaction sites within the body.  Biomimetic design of devices can 
take advantage of the natural processes of the body to be highly selective and effective, 
enabling the ability to localize and maintain treatment at a specific area within the body.  
However, to be both effective and selective, a thorough knowledge and understanding of 
the biological environment is a necessity. 
Gastrointestinal Motility 
The alimentary canal’s physiology and motility play a key role in determining the 
fate of a drug delivery system.  The specific state of the digestive system poses particular 
obstacles in allowing the therapeutic to be delivered as engineered.  In developing site-
specific delivery systems, one must take into consideration both the physiology and 
motility to better design the dosage form.  After passing through the mouth and 
esophagus, the delivery system enters the stomach.  The stomach is composed of three 
distinct muscular components, the fundus, the antrum, and the pylorus, and its primary 
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function is to mix and grind food up into small enough particles to pass through the 
pylorus (2).  
The fundus is composed of three layers of muscle—inner circular layer, outer 
circular layer, and outermost oblique layer—which relax upon the entry of food and 
contract to force the food towards the antrum region.  Through phases and contractile 
activity, the antrum functions both as a pump and a grinding mill.  The pylorus possesses 
the ability to restrict the exit of liquids, prevent the passage of large particles, and close 
completely during the antral stroke. Once passing through the pylorus sphincter into the 
duodenum, the contents of the GI tract can be subjected to propagated bursts of 
contractions that often occur in association with propagated antropyloric pressure waves 
as the antroduodenal emptying stroke, isolated contractions, or retroperistaltic 
contractions that return the contents back into the stomach.  The major motility function 
of the duodenum area is to further move the contents and the emptied gastric chyme 
downstream and is the site where the major digestive processes occur.  The stomach and 
the duodenum work in a closely integrated fashion to control gastric emptying that is 
suitable for the person’s physiological and emotional state.   
Intestinal motility (small and large) is a broad generalization that refers to 
intralumenal flow, the motions of the wall that cause this flow, and the control systems 
that regulate these wall motions (28).  The two muscle layers responsible for most of the 
motions associated with movement are the outer longitudinal and the inner circular 
muscle layers.  The epithelium layers consist of the various types of cells lining the 
intestinal lumen including enterocytes and goblet cells, the cells responsible for 
absorption and mucus secretion, respectively.  The small intestine moves its contents 
caudally with accompanying stirring and mixing.  The two wall contractions responsible 
for the motility are ring contractions and sleeve contractions.  Ring contractions are the 
 14
type of muscle movement most often associated with intestinal transit.  The rings begin 
as circumferential indentations and then sweep across the small intestine.  The point of 
inception and distance of movement is controlled by both the nervous system and 
hormones, reflecting the digestive needs of the luminal contents.  These contractions are 
associated with a periodicity at a specific level of the small intestine with a drop in 
frequency caudally along the intestine.  This particular type of contraction is what is often 
referred to as peristalsis.   
Sleeve contractions are responsible for the mixing of the lumenal contents by 
shifting fluid between the inside and outside of the lumen.  Both types of major 
contractions work in a concerted effort to spread and mix the lumenal contents across the 
mucosal surface to achieve maximum absorption.  The viscosity of a suspension in the 
lumen has an effect on its GI transit due to its greater inertial ability to resist propulsive 
contractions (2).  Therefore, a dosage form with a high viscosity has the capability of 
increasing the residence time of the therapeutic.  To further enhance the intimate contact 
of the dosage form with the absorption site, the delivery system can be engineered with 
molecular characteristics capable of achieving greater bioadhesion, specifically 
mucoadhesion. 
Mucous Gel Layer 
The mucous gel layer, the target site for mucoadhesion, serves to protect and 
lubricate epithelial surfaces such as those of the gastrointestinal, respiratory, and 
urogenital tracts while still allowing specific interactions to occur by means of their 
complex structure (29).  Mucins are filamentous glycoproteins that are the major 
component of the mucus that lines most hollow organs of the body and those organs that 
come into contact with exogenous environments.  The family of mucin biopolymers is 
characterized by a protein backbone that consists of tandem repeat units of peptide 
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sequences, typically serine- and threonine-rich, which contain O-linked glycans (30).  
There are currently 17 different mucins (Table 2.1) all of which contain extended 
domains of the variable number of tandem repeats (VNTR), which are serine-, threonine-, 
and/or proline-rich (STP-rich regions).  There are two structurally and functionally 
distinct classes of mucins which can either be classified as secreted gel-forming mucins 
or transmembrane mucins (31).   
Secretory mucins such as MUC2, MUC5AC, MUC5B, MUC6, MUC7, and 
MUC8 are secreted by the goblet cells and receive extensive O-glycosylation in the cis to 
trans Golgi of the cell. These mucins have the capability to polymerize through disulfide 
bond linkages formed between the cysteine residues found in the von Willebrand factor 
(VWF-)-like D domains (32).  O-glycosylation begins in the cis Golgi and is completed 
after passing through the trans Golgi after which a significant increase occurs in the 
biopolymer’s apparent molecular weight (30).  The non-tandem repeating regions of 
MUC2 have over an 8% cysteine content which are positioned at the ends of the proteins 
and form dimers in the endoplasmic reticulum of the goblet cells.  Along with 
glycosylation, polymerization occurs in the cis to trans compartments of the Golgi.  
Polymerization of the biopolymers begins with tail-to-tail dimerization at the C-terminal 
followed by head-to-head multimerization at the N-terminals (33).  
The gel layer can be divided into one that is loosely adhered and one that is firmly 
adhered.  The firmly adhered is composed of the membrane mucins and is approximately 
20 µm in upper small intestine for rats.  The loosely adhered mucus is composed of the 
secreted mucins such as MUC2 and MUC3.  This gel layer is approximately 150 µm in 
the upper small intestine for rats (34).  The mean turnover time of the mucous gel layer 
has been shown to vary between 47 and 270 min, which would indicate a significant 
factor in designing mucoadhesive drug delivery systems (35).  The mucous gel layer 
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itself represents an unstirred water layer which impedes drug diffusion and adsorption 
across the epithelium. 
MUC2 and MUC3 mucin mRNAs are prominently expressed in the small 
intestine, the most favorable site for orally delivered therapeutic absorption.  The goblet 
cells are responsible for the MUC2 synthesis, whereas the enterocytes produce MUC3 
(36).  MUC2 is also the prominent mucin in the large intestine; therefore, its structure and 
functionality play a key role in the successful development of mucoadhesive drug 
delivery systems.  The biopolymer MUC2 has a molecular weight of approximately 3,000 
kDa (37) and is responsible for the formation of the viscoelastic gel (38) that covers the 
lumen of the small and large intestine.  The protein backbone consists of over 4,500 
residues which can be divided into three major structural domains:  tandem repeat array, 
carboxyl-terminal domain, and amino-terminal domain.   
Taking into consideration the steric constraints imposed by a relatively heavily O-
glycosylated tandem repeat array domain, the mucin molecules are rigid and extended, 
taking on a filamentous structure (39).  The other two domains are non-glycosylated and 
cysteine-rich which provide the groups necessary for disulfide bond formation and mucin 
polymerization.  The mucus that is formed by multimers of MUC2 protects the 
underlying epithelial cells along the digestive tract from the acidic and proteolytic 
environment presented by the lumen, the shear forces naturally exerted during the 
digestive process, and the microorganisms and bacteria responsible for infections and 
disease.  The gel-forming capabilities are directly affected by proteolytic degradation or 
mercaptoethanol reduction, signifying the importance of the presence of disulfide bonds 
and biopolymerization on the formation and stability of the gel layer (40).  The mucous 
gel layer can be considered a loosely, physically entangled, biopolymeric network which 




The mucous gel network serves as a target for mucoadhesive biomaterials 
composed of polymer chains with the ability to interpenetrate and bridge the interface 
between the drug carrier and the mucus (19, 41).  Polymer chains available at the surface 
of the biomaterial are often employed to serve as adhesion promoters (42-45).  With the 
polymer chains at the periphery of the delivery system, they are able to develop an 
intimate contact with the mucous gel layer, diffuse across the interface, and form 
entanglements with the mucous gel layer.  Once across the polymer/gel boundary, further 
non-covalent mechanisms can occur to strengthen the bond.  The enhanced bridging is a 
result of further chain entanglement, secondary bonding, or electrostatic interactions.  For 
further enhancement of the adhesive bond formed between a delivery system and the 
mucous gel layer, tethered polymers, both anionic and cationic, can be used to create a 
synergistic effect in developing a more effective mucoadhesive delivery system (46-49).  
Polymer chains with one of their ends tethered onto a surface have found uses in a 
wide variety of applications such as surface energy enhancement (wetting), colloidal 
stability, biocompatibility, and adhesion (50-52).  The pioneering work on the 
conformation of tethered polymers (Figure 2.4) was developed by de Gennes (51).  The 
thickness of the polymer layer was shown to be dependent on the surface coverage, σ, of 
the chains, and either a mushroom or a stretched configuration is developed when in the 
low or high surface coverage regime, respectively.  The thickness of the layer is directly 
proportional to the degree of polymerization and the width of the monomer (Figure 2.5). 
Brochard-Wyart et al. (50) further elucidated on the role of grafted chains as 
adhesion promoters and provided evidence of maximum adhesion enhancement at an 
intermediate surface coverage (Figures 2.6-2.8). These results provided evidence that 
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polymers attached to a surface take on three distinct regimes: separate mushrooms, 
overlapping mushrooms, and partial interdigitation.  The intermediate regime provides 
the greatest adhesion energy due to a higher percentage of chains participating in 
interdigitation. 
The theory surrounding polymers attached to hydrogels was further developed in 
our laboratory by Huang et al. (48, 49) and included systems composed of two hydrogels 
such as those involved with the process of mucoadhesion.  This theoretical framework 
provided evidence of the probability of finding both the chains and the free end segment 
outside the base gel available for interpenetration.  Both were dependent on the surface 
coverage of the polymer tethers, with a large number of the chains and free ends present 
outside the base gel at low and intermediate coverage.  However, at high coverages the 
chains penetrated back into the base gel due to the intermolecular interactions between 
neighboring chains.  Adhesion enhancement associated with the base and target gel 
(mucus layer) was also shown to be maximized at an intermediate coverage.  Therefore, 
in designing biomaterials for mucoadhesive applications, the surface coverage of grafted 
polymer chains can be controlled to achieve adhesion enhancement through polymer-gel 
interpenetration (53). 
Thiomers 
Thiolated polymers, or thiomers, have received considerable attention as potential 
mucoadhesive polymers (54).  The list of thiol-bearing polymers includes chitosan-
cysteine, chitosan-thiobutylamidine, chitosan-thioglycolic acid, poly(acrylic acid)-
cysteine, poly(acrylic acid)-cysteamine, carboxy-methylcellulose-cysteine, and alginate 
cysteine.  The nature of their action differs as compared to PEG adhesion promoters in 
that a covalent disulfide bond is formed between the cysteine residues on the mucin 
backbone and the free thiols along the mucoadhesive polymer backbone.  This provides a 
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stronger bond as compared to the formation of weak non-covalent bonds such as 
hydrogen bonds, van der Waals forces, and electrostatic interactions.  These thiomers 
have the ability to mimic what naturally occurs in the secretion of the mucous gel layer 
where oligomers of mucins are joined by disulfide bonds. 
Cationic thiomers have largely been thiolated chitosan whereas anionic thiomers 
exhibit carboxylic groups as the anionic moieties.  The reactions typically employ 
carbodiimide chemistry to form an amide bond between the primary amino group of the 
chitosan and the carboxylic acid group of the attached ligand, or the reverse for anionoic 
polymers.  Stability of the free thiol is maintained through an inert environment or a 
lowered pH.  At a pH < 5, the number of thiolate anions is significantly reduced, thereby 
decreasing the oxidation of the thiol groups.  Ellman’s agent can be used to determine the 
amount of thiol groups present on the polymers backbone. 
The interaction between the thiomers and mucin molecules can be attributed to 
the formation of a disulfide bond which occurs through either a thiol/disulfide exchange 
reaction or through the oxidation process of free thiols.  Mucins covering the surfaces of 
the body typically all possess cysteine-rich subdomains along the mucin backbone which 
are free of O-glycosylation, allowing for interaction between other mucins and thiomers 
to occur.  Disulfide bond formation is largely dependent on thiolate anion concentration.  
The anion concentration is further dependant on the pKa of the thiol group, the pH of the 
thiomer (microclimate), and the pH of the surrounding medium. 
Biopolymers 
Biopolymers include polymers that are found in nature such as chitosan, alginates, 
and lectins, to name a few.  Chitosan (Figure 2.10) has been used as a bioadhesive due to 
its ability to bind mucin through both i) electrostatic forces between the positively 
charged amine and the charged acidic groups of sialic acid and sulphonated residues and 
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ii) hydrophobic forces between the acetyl groups and fucose residues (55).  Chitosan 
coated microparticles have been shown to adhere well to the intestine of animals when 
administered intraduodenally to rats, and the system maintained the plasma concentration 
for an extended period of time (56).  Other polysaccharides can be found widely in the 
literature for their use as mucoadhesives, but their interactions are based on hydrogen 
bonding with their sedimentation ratios being close to unity.  This sedimentation ratio 
indicates that there is little to no interaction on the molecular level between these other 
polysaccharides and mucin (55). 
Lectins, plant proteins that bind specifically to carbohydrate groups found on 
mucins and cell membranes, have been introduced as a way to circumvent the problems 
associated with non-specific binding of the first generation bioadhesives to sloughed 
mucus or other components present in the gastrointestinal tract (57-59).  Binding affinity 
relies heavily upon the conformation the lectin takes which can be significantly affected 
by the immobilization procedure and the application environment.  Biomimetic 
mucoadhesive drug delivery systems have further evolved to employ fimbriae, long 
filamentous protein projections found on the surface of bacteria, as specific mucin 
binding moieties (60). 
TISSUE ENGINEERING 
Biomaterials (polymers, ceramics or metals) have made significant advances in 
the treatment of damaged tissue and organs and organ dysfunction.  They have the 
capacity to restore biological function while maintaining compatibility with the 
surrounding biological environment (biocompatibility).  The complexity and number of 
variables involved in achieving success with the usage of biomaterials has limited the 
understanding to a generalized scale without focusing on the fundamental mechanisms.  
An objective of recent biomaterial development has been to interact with the biological 
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environment more specifically as opposed to non-specific interactions based on the 
generalized properties such as cell’s negative surface charge and common characteristics 
of the extracellular matrix. 
The use of biomimetic materials, materials that mimic a biological environment to 
elicit a desired cellular response, provides a means to obtain specific interactions (61).  
One of the critical steps in achieving success with the application of a biomaterial is 
cytoadhesion.  The critical processes involved with cell adhesion include cell attachment, 
cell spreading, organization of an actin cytoskeleton, and formation of focal adhesions.  
Cellular adhesion, more specifically cell attachment, can be made more effective through 
the deployment of ligands that interact specifically with integrins (receptors present at the 
surface of a cell) present in the environment where the biomaterial is applied (62-64).  
One of the more commonly used approaches is the attachment of an RGD (Arg-Gly-Asp, 
Arginine-Glycine-Aspartic acid) peptide to the biomaterial surface to enhance cell 
adhesion by targeting the integrin receptors on a cell’s surface (64). 
Biomaterial surface modifications are not limited to ligand-integrin receptor 
mediated adhesion.  Heparin-binding peptides and lectins have also been used to increase 
cell attachment.  Proteoglycans are the targets for the heparin-binding peptides whereas 
the carbohydrate-rich glycocalyx serves as the binding target for lectins.  As the 
knowledge of the processes involved with cellular adhesion is increased, more effective 
biomaterials can be developed which provide the necessary surface characteristics to 
promote adhesion.  More effective cellular adhesion will aid in a biomaterial’s success 
which will result in better treatments for diseases and increased quality of life for these 
patients. 
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ADHESION OF MICROBES AND PATHOGENS 
The fundamental understanding of how microorganisms are able to adhere to 
materials has a broad impact that ranges from having the ability to effectively clean 
contaminated soil, developing materials resistant to biofouling, and preventing 
inflammation and rejection due to biofilms formed on a biomedical implant’s surface.  
Just as in the case of a bioadhesive polymer, the surface characteristics of the bacterium, 
the bacterium/material interface, and the surface characteristics play a pivotal role in 
determining whether or not a bacterium is capable of initial attachment. 
Forces responsible for this initial attachment can be attributed to electrostatic 
forces, van der Waals, hydrophobic, water movement, or other specific interactions.  
Factors such as the residence time, loading force, pH, and ionic strength have been shown 
to be important in the adhesion of microbes to surfaces (65).  Atomic force microscopy 
(AFM) has provided valuable information regarding molecular-level interactions between 
microbial and material surfaces through the use of novel biopolymer immobilization 
techniques such as biopolymer-coupled-carboxylated dextrans (66).  Entire bacteria have 
been immobilized to glass to study the effect of pH on the surface polymer’s 
conformation which drives the ability of the microbe to adhere to a surface (67).   
Developing a fundamental understanding of the receptor/binding molecule 
interaction has implications in understanding how diseases are spread.  Human-to-human 
virus transmission of certain strains of influenza, or the lack thereof, can be linked to the 
binding preference of the virus to certain carbohydrates present on epithelium surfaces.  
Human and avian influenza viruses bind specific sialic acids linked to galactose through 
an α-2,6 or an α-2,3 linkage, respectively (68).  The reason why widespread transmission 
of this virus from infected avian populations to human ones has not occurred can be 
attributed to this subtle binding preference. 
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FUTURE DIRECTIONS AND CONCLUSIONS 
The field of bioadhesion is one that is rapidly evolving to aid in the development 
of materials that are capable of more effective drug delivery, enhanced disease treatment, 
and the prevention and understanding of disease transmission.  Biomimetic materials are 
quickly replacing those first-generation materials that relied heavily on the non-specific 
interactions they had with the natural tissue.  Drug delivery systems are employing 
nature’s method of covalent bond formation (thiomers) and specific interactions (lectins) 
through carefully designed surfaces (tethered surfaces).  Tissue engineering matrices are 
incorporating macromolecules that the body is capable of recognizing and utilizing in the 
rehabilitation of organ dysfunction and failure.  Some disease transmissions can be 
attributed to the ability of a microorganism or pathogen to adhere to an epithelial surface, 
and the fundamental understanding of this binding event could lead to more effective 
ways of prevention and treatment. 
Successfully engineered materials for bioadhesive applications, or the prevention 
of bioadhesion in some instances, will continue to incorporate biologically relevant 
moieties to aid in their effective use by the biological host.  Carbohydrates and their role 
in cell-cell and cell-matrix interactions are becoming increasingly important, and both the 
incorporation of carbohydrate structures and their binding molecules will be crucial for 
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Table 2.1   Mucins found in the human body.  Adapted from Ref. (30). 




MUC2 S 11p15.5 
MUC5AC S 11p15.5 
MUC5B S 11p15.5 
MUC6 S 11p15.5 
MUC7 S 4q13-21 
MUC8 S 12q24.3 
MUC1 M,S 1q21 
MUC3 M,S 7q22 
MUC4 M,S 3q29 
MUC11 M 7q22 
MUC12 M 7q22 
MUC13 M 3q13.3 
MUC15 M 11p14.3 
MUC16 M 19p13.2 
MUC17 M 7q22 
MUC20 M 3q29 




 Figure 2.1 Bioadhesion refers to the molecular contact (adherence) of two tissues 
through the application of a bioadhesive between these two surfaces.  











































Figure 2.2 Examples of electrostatic forces occurring between amino acids.  These 
forces are due to (a) the association of two ionic protein groups such as 
Lysine (Lys) and Glutamic acid (GLU) or (b) the dipole-dipole interactions 
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Figure 2.3 Chemical structure of commonly employed poly(acrylic acid)-based 
materials in mucoadhesive drug delivery systems.   934P is crosslinked with 
allyl sucrose, 974P with allyl pentaerythritol, and AA-1 with divinyl glycol.  
A small amount of the acrylic acids are neutralized to potassium acrylate 




Figure 2.4 Polymer tethers grafted at a low surface coverage (σ → 0) and in a pure 
solvent.  The dashed circle has a diameter which is 2 x RF (Flory radius).  
The grafted chains are separated by a distance, D, that is directly 
proportional to the monomer size (a) and inversely proportional to the 




Figure 2.5 Tethered polymers in a good solvent take a strongly stretched conformation, 
and the thickness of this stretched polymer layer, L, is directly proportional 
to the degree of polymerization (N), the monomer size (a), and the surface 





Figure 2.6 Tethered polymers take on distinct conformations when exposed to a 






Figure 2.7  At intermediate surface coverages, the tethered polymer layer 






Figure 2.8 At high surface coverages, some polymers interpenetrate into the 





Figure 2.9 The theoretical framework developed in our laboratory by Huang et al. (48) 
includes the tethered polymers, the base gel to which these polymers are 
tethered, and the target gel representative of the tissue to be adhered.  The 
position at z = 0 represents the base gel surface plane and d is the distance 


























Figure 2.10 Structure of chitosan, which is derived by partially deacetylating chitin.  The 
number of acetyl groups (m) and primary amine groups (n) is controlled 
through the extent of deacetylation. 
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Chapter 3:  Research Objectives 
The main goals of this research were to (a) synthesize polyacid pH responsive 
biomaterials in the form of microparticles, (b) characterize the physicochemical 
properties of these materials, (c) synthesize poly(ethylene glycol)-tethered polyacid 
complexation hydrogel microparticles, (d)  characterize the physicochemical properties of 
these materials, (e) formulate these particles into multifunctional novel minitablet drug 
delivery systems capable of controlled release and adhesion, and (f) evaluate the gel/gel 
adhesive characteristics of these materials. 
The aim of the study presented in Chapter 4 was to synthesize and characterize 
polyacid pH responsive biomaterials in the form of microparticles.  The objective was to 
examine if microparticles possessing a stimuli response could be successfully synthesized 
to meet the requirements necessary for their successful incorporation into a drug delivery 
system.  Methacrylic and acrylic acid were the two monomers that were investigated.  
The amount of tri-functional crosslinking agent was varied to investigate its effect on the 
structure and dynamics of the microparticles. 
The aim of the study presented in Chapter 5 was to synthesize and characterize 
PEG-tethered polyacid complexation hydrogels in the form of microparticles.  The 
objective was to examine the effect of the addition of the PEG tether on the synthesis and 
the dynamics of the materials synthesized.  The gel/gel adhesive characteristics of gel 
suspensions of the hydrogels were elucidated. 
The aim of the study presented in Chapter 6 was to formulate these polyacid pH 
responsive and complexation hydrogels into novel minitablet drug delivery systems.  The 
effect of the monomer type, crosslinking agent, molecular mass of PEG tether, and 
amount of PEG tether on the release of a model compound were examined.  The 
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parameters necessary for the development of a multifunctional drug delivery system were 
outlined. 
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Chapter 4:  Synthesis and Properties of Lightly Crosslinked 
Poly((meth)acrylic acid) Microparticles Prepared by Free Radical 
Precipitation Polymerization 
INTRODUCTION 
Poly(carboxylic acid)-containing materials have been investigated for a diverse 
range of applications such as coatings (1, 2), superabsorbents (3-5), adhesives (6, 7), and 
drug delivery carriers (8-18).  Through the combination of the later two concepts, drug 
delivery systems (DDS) employing poly(carboxylic acid)-containing hydrogels have the 
ability to contribute to the development of an adhesive bond between the drug carrier and 
the biological target of the therapeutic, acting as bioadhesive drug delivery systems (19-
24).  The prolonged residence time of a therapeutic at the site of administration, whether 
it is the gastrointestinal or respiratory tract, ocular cavity, or dermal layers, enhances the 
overall effectiveness of the drug leading to a higher bioavailability.  Hydrogels possess 
the ability to swell upon contact with aqueous solutions due to the hydrophilic nature of 
the polymers and the presence of either physical or chemical crosslinks.  Upon the 
introduction of ionizable carboxylic acids as pendant groups, the hydrogel network is 
capable of being triggered by an environmental stimulus such as pH (25-27). 
By utilizing the pH shift that occurs as an oral DDS is transported from the acidic 
environment of the stomach to the near-neutral duodenum and small intestine, both drug 
release and adhesion can be triggered (28).  Micro- and nano-sized devices and systems  
(29, 30) are desirable for their use in oral drug delivery due to their ability to be 
formulated into conventional dosage forms and the ease of administration of particle 
suspensions.  For the development of conventional dosage forms such as tablets and 
capsules, the rate controlling polymer must possess a high degree of compressibility and 
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be in a particulate state that can be easily formulated with the active pharmaceutical 
ingredient (API).  The synthesis of highly compressible microparticles is desirable to 
provide a polymeric material that is effectively utilized in these DDS.  The integration of 
these biomaterials into a DDS that utilizes the polymer as a carrier is also facilitated by 
the synthesis of microparticles. 
The aim of this work was to synthesize terpolymer microparticles prepared from 
pendant carboxylic acid monomers, pendant potassium carboxylate monomers, and a 
trifunctional pentaerythritol and characterize the polymer’s physicochemical properties as 
a function of monomer and crosslinking agent composition. 
MATERIALS AND METHODS 
Materials 
Methacrylic acid (MAA, inhibited with 250 ppm hydroquinone), anhydrous 
potassium carbonate (K2CO3), and ethyl acetate (EtAc) were obtained from Fisher 
Scientific and used as received.  Acrylic acid (AA, inhibited with 200 ppm 
hydroquinone) was obtained from Sigma Aldrich (Milwaukee, WI) and was used as 
received.  Allyl pentaerythritol (APE), pentaerythritol triacrylate (PETA), and di(4-tert-
butylcyclohexyl) peroxydicarbonate (BCHPC) were kindly supplied by Perstorp Polyols 
(Toledo, OH), Sartomer (Exton, PA), and Degussa Initiators (Elyria, OH), respectively.  
All other chemicals were of reagent grade and used as received. 
Synthesis 
In a typical thermally-initiated free radical precipitation polymerization, (M)AA,  
K2CO3, and deionized distilled water (ddH2O) were combined and mixed to form a 
homogeneous mixture, allowing the escape of the neutralization by-product carbon 
dioxide.  The crosslinking agent, APE or PETA, was dissolved in ethyl acetate.  The 
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monomer mixture and crosslinking agent were added to a four-necked round bottom flask 
equipped with an overheard stirrer, nitrogen purge, and condenser containing the 
polymerization solvent EtAc.  Following a 20 minute purge with nitrogen, the initiator 
BCHPC dissolved in the polymerization solvent was added to the vessel and further 
purged for an additional 10 minutes.   
The molecular structures of the monomer, crosslinking agent, and thermal 
initiatior are shown in Figure 4.1.  The vessel was placed in a thermostatic bath at 50°C 
where precipitation was evident in a matter of minutes.  The reaction was allowed to 
proceed for 16 hours to ensure a high percentage of monomer conversion.  Following the 
polymerization, the particle slurry was centrifuged and washed with fresh ethyl acetate 
and dried using a rotary evaporator at elevated temperature and reduced pressure 
(90°C/40 mmHg).  Table 1 lists the various polymer microparticles prepared. 
Characterization 
Particle suspensions of the microparticles were prepared using ethyl acetate, and 
the particle size distribution was determined with a laser light diffraction particle analyzer 
(Malvern Mastersizer-S, Malvern Instruments Ltd., Worcestershire, UK).  The 
measurement was repeated three times.  A scanning electron microscope (SEM, Hitachi 
Model S-4500, Hitachi Ltd., Tokyo, Japan) was used to obtain SEM photographs.  The 
vacuum-dried polymer microparticles were mounted on an aluminum stage using double-
sided carbon conductive tape and coated with gold for 45 seconds with a sputter-coater 
(Pelco Model 3, Pelco Int., Redding, CA) in an argon atmosphere. 
Pellets containing 1 mg of sample and 150 mg of KBr were prepared on a Carver 
laboratory press using a 15,000 lb compression force.  Infrared spectra of the 
microparticles were obtained in the wavenumber range of 400-4000 cm-1 on a Fourier 
transform infrared spectrophotometer (FT-IR, Thermo Mattson Infinity, Thermo Electron 
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Corp., Waltham, MA) in transmission mode equipped with a KBr beamsplitter and 
DTGS detector.  Each spectrum is an average of 64 scans at a resolution of 1 cm-1.   
The thermal properties of the microparticles were characterized using a 
differential scanning calorimeter (DSC, MDSC 2920, TA Instruments, New Castle, DE).  
Approximately 10-15 mg samples were analyzed at a sample rate of 10°C/min over the 
range of 80°C to 160°C for poly(acrylic acid) and 80°C to 300°C for poly(methacrylic 
acid) using a heat/cool/heat method to erase the thermal history.   
The equilibrium weight swelling ratio of the polymeric hydrogel microparticles 
was determined by carefully weighing 50 mg of dried particles and combining them with 
35 mL of NaHCO3 solution (1.5 g / 100 mL).  The suspension was agitated for 60 min 
and then centrifuged for 60 min at 2000 rpm, carefully discarding the supernatant.  The 
pellet was resuspended in an additional 35 mL of NaHCO3 solution and agitated for 60 
min.  The suspension was centrifuged at 2000 rpm for 60 min, carefully removing the 
supernatant, and the weight of the gelled mass was determined.  This procedure was also 
carried out in a 0.1 N HCl solution.   
Potentiometric titrations were carried out on aqueous solutions of the 
microparticles.  Approximately 400 mg of polymer were slowly added to 400 mL of 
deionized distilled water.  During the polymer addition, the solution was agitated using a 
three-blade marine style propeller at 1000 rpm.  The particles were allowed to agitate and 
hydrate for 15 minutes before recording the initial pH of the suspension.  After a 
reduction in the agitation speed, titration was performed using a 1 N NaOH solution.  The 
pH was allowed to equilibrate before any further addition was made. 
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RESULTS AND DISCUSSION 
Particle Size and Morphology 
All monomers, crosslinking agent, and initiator are soluble in the ethyl acetate 
polymerization solvent.  Upon heating the reaction mixture to the polymerization 
temperature, oligomers begin to form as outlined in Figure 4.2.  As these oligomers grow 
into polymers, the polymers become insoluble in the solvent.  At this point, precipitation 
is evident and particle formation occurs.  Microparticle formation occurs through the 
continuation of agglomeration of these primary particles.  Polymerization of copolymers 
of PMAA and PAA and the crosslinked terpolymers result in no significant differences in 
their particle size.   
As determined using laser light diffraction, the particle size of both copolymers 
and terpolymers as suspensions in EtAc results in a D(v, 0.5) of approximately 15 µm 
and D(v, 0.9) of approximately 30 µm. Particles composed of MAA show significantly 
different primary particle morphology as can be seen in Figures 4.3 and 4.4.  This is due 
to the additional polymer growth that occurs at the primary particle’s surface as opposed 
to negligible growth upon the PAA surface.  Through polymer bridging and crosslinking 
that occurs within the primary particles of both monomers, the resulting microparticles 
are physically and chemically inseparable.  However, for the copolymers, polymer 
dissolution is achieved upon polymer neutralization indicating the absence of 
crosslinking. 
FT-IR Spectroscopy of Poly(carboxylic acid) Microparticles 
Figure 4.5 shows the IR spectra for both crosslinked PMAA and crosslinked PAA 
microparticles recorded at ambient temperature in the dried state.  Both structures exhibit 
the characteristic C=O stretching, with the acrylic acid carbonyl stretching occurring at 
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1710 cm-1 and methacrylic acid at about 1715 cm-1.  The potassium carboxylate in both 
materials is represented by the shift in the carbonyl stretching to approximately 1560   
cm-1.  The stretching of C=O coupled with the bending of O-H is responsible for the 
peaks occurring in the region between 1180 and 1270 for both crosslinked PMAA and 
crosslinked PAA (31, 32).  The symmetric bending of the CH3 planar deformation occurs 
at 1391 cm-1 for crosslinked PMAA.  The CH2 deformation bending gives a band about 
1456 cm-1 for both structures with CH3 deformation asymmetric bending at about 1488 
cm-1.  O-H bonded groups give rise to vibration bands at about 2620 cm-1 for both 
materials.  CH2 stretching exhibits bands at about 2948 cm-1, while the spectrum of 
crosslinked PMAA exhibits the asymmetric vibration of the CH3 group at 2997 cm-1.  
The broad region from 3100 to 3500 shows the O-H stretching (3100 cm-1) for both 
structures along with the free O-H groups at approximately 3440 cm-1 for crosslinked 
PMAA. 
Differential Scanning Calorimetry 
The glass transition temperature, Tg, of potassium acrylate is approximately 
194°C, and due to its presence in the uncrosslinked PAA copolymer, the Tg is expected to 
be higher than the reported value of 105°C for PAA (33).  As the pentaerythritol 
crosslinking agent was incorporated into the networks, the Tg passed through a transition 
regime indicating heterogeneous crosslinking or branching that occurred, thus limiting 
the mobility of the polymer network as shown in Figure 4.7.  As the crosslinking agent 
was increased to 0.43 mol %, a significant increase in the glass transition indicated 
homogenous crosslinking, which was verified by the polymer microparticles’ insolubility 
in aqueous solutions as compared to the 0.2 mol % crosslinked PAA and the linear 
copolymer.  As the level of crosslinking was increased, the mobility of the polymer 
chains was decreased, which is evident by the higher glass transitions. 
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Upon heating of the PMAA copolymer and terpolymers to 300°C, a large 
endotherm is observed indicating dehydration and anhydride formation (31).  The glass 
transition observed after this initial heating and cooling step is shown in Figure 4.6.  The 
PMAA copolymer exhibits a higher Tg than the PAA due to both the mobility inhibition 
of the methyl group and the anhydride formation.  As the mobility is hindered by the 
presence of crosslinks, the Tg increases with more significance than the crosslinking 
effects of PAA.  This is due to the synergistic effects of both crosslinking and anhydride 
formation and their effects on the mobility of the chains in the network. 
Physicochemical Properties of Poly(carboxylic acid) Microparticles 
The equilibrium weight swelling ratio, q, was calculated using equation (4.1), 
where Ws and Wd are the weights of swollen and dry polymer, respectively. 
  ds WWq=         (4.1) 
The crosslinked PAA samples show a significantly higher equilibrium swelling 
ratio in the carbonate buffer than polymers containing MAA at similar crosslinking ratios 
as can be seen in Figure 4.8.   
 This is due to the more hydrophilic acrylic acid.  The presence of the methyl 
group in methacrylic acid imparted more hydrophobicity to the hydrogel structure, 
limiting the amount of solution uptake.  The swelling of the carboxylic acid 
microparticles was heavily dependent on the crosslinking ratio, with the heavier 
crosslinked particles exhibiting a significantly lower swelling ratio.  The pH dependent 
swelling of these polymers was evident by the effects of the acidic medium on the 
equilibrium swelling ratio.  Both crosslinked PAA and crosslinked PMAA exhibit a 
significantly lower swelling ratio in 0.1 N HCl than in the carbonate buffer due to 
protonation of the carboxylic acid groups and the lack of ionization.  Due to the ability of 
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crosslinked PMAA to form stronger inter- and intra- polymer complexation at a pH 
below its pKa, the swelling ratio of these polymers was lower than crosslinked PAA. 
Ionization of the acidic groups caused the polymer chains to repel one another, expanding 
the hydrogel network.   
The number of carboxyl groups, nCOOH, present in the microparticles was 
calculated according to equation 2, where V is the volume of NaOH consumed at the 
endpoint of the titration, N is the normality of the NaOH solution, and mparticles is the 
weight in mg of microparticles.   
   particlesNaOHNaOHCOOH mNVn )02.45( ••=     (4.2) 
The degree of neutralization, αn, was calculated according to equation (4.3) where 
CBase, CH+, COH-, and CCOOH are the molarities of base, hydrogen ions, hydroxide ions, 
and  microparticle contributed carboxylic acid in the titration solution (33). 
  COOHOHHBasen CCCC )( −+ −+=α      (4.3) 
The molarity of microparticle contributed carboxylic acid was determined from 
nCOOH according to equation 4. 
  ( ) ( )solutiontotalparticlesCOOHCOOH VmnC ••= 02.45    (4.4) 
The apparent dissociation constant, pKapp, was obtained from the degree of 
dissociation and pH according to equation (4.5).  The value of the pKa, which 
corresponds to αd = ½, was determined from the titration curve.   
  [ ]nnapp pHpK αα )1(log −+=      (4.5) 
Crosslinked PAA microparticles exhibit a pKa of 6.9 with the particles containing 
approximately 0.55 carboxyl groups.  Crosslinked PMAA microparticles exhibit a pKa of 
7.4 and contain approximately 0.44 COOH groups.  The difference in pKa is derived from 
the slight difference in the pKa of the acidic monomers.  The lower number of carboxyl 
groups as compared to the theoretical maximum is due to the presence of the potassium 
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carboxylates.  Also, due to the methyl group, the crosslinked MAA particles possess a 
lower amount of carboxyl groups. 
CONCLUSIONS 
Microparticles composed of (meth)acrylic acid were successfully prepared using a 
thermally-initiated free-radical precipitation polymerization in ethyl acetate.  Particle size 
was shown to be dependent on crosslinking and monomer.  Slight morphological 
differences were observed due to differing polymer growth at the surface of the primary 
particle.  Structural differences were observed and interpreted using FT-IR with only 
slight differences being observed due to the presence of the methyl group.  The glass 
transition behavior of the materials was significantly different with MAA-based materials 
exhibiting a much higher Tg.  The Tg was also heavily dependent on the amount of 
crosslinking present in the network.  Crosslinked PAA possesses a higher swelling ratio 
than crosslinked PMAA with both polymers exhibiting pH dependent swelling. 
 51
 REFERENCES 
1. Ditsch A, Laibinis PE, Wang DIC, and Hatton TA, Controlled clustering and 
enhanced stability of polymer-coated magnetic nanoparticles, Langmuir, 21:6006-
6018, 2005. 
2. Hilt JZ, Gupta AK, Bashir R, and Peppas NA, Ultrasensitive biomems sensors 
based on microcantilevers patterned with environmentally responsive hydrogels, 
Biomed. Microdevices, 5:177-184, 2003. 
3. Askari F, Nafisi S, Omidian H, and Hashemi SA, Synthesis And Characterization 
Of Acrylic-Based Superabsorbents, J. Appl. Polym. Sci., 50:1851-1855, 1993. 
4. Li A and Wang AQ, Synthesis and properties of clay-based superabsorbent 
composite, Eur. Polym. J., 41:1630-1637, 2005. 
5. Argade AB and Peppas NA, Poly(acrylic acid) poly(vinyl alcohol) copolymers 
with superabsorbent properties, J. Appl. Polym. Sci., 70:817-829, 1998. 
6. Soeno K, Suzuki S, Taira Y, Sawase T, and Atsuta M, Influence of mechanical 
properties of two resin cements on durability of bond strength to dentin after 
cyclic loading, Dent. Mater. J., 24:351-355, 2005. 
7. Sosson F, Chateauminois A, and Creton C, Investigation of shear failure 
mechanisms of pressure-sensitive adhesives, J. Polym. Sci. Pt. B-Polym. Phys., 
43:3316-3330, 2005. 
8. Bell CL and Peppas NA, Modulation of drug permeation through interpolymer 
complexed hydrogels for drug delivery applications, J. Control. Release, 39:201-
207, 1996. 
9. Bures P and Peppas NA, Structural and Morphological Characteristics of Carriers 
Based on Poly(acrylic acid), Polym. Prepr., 40:345-346, 1999. 
10. Ficek B and Peppas N. Biomaterials for Drug and Cell Delivery. in Materials 
Research Society. 1994. Pittsburgh, PA. 
11. Lopez JE and Peppas NA, Effect of poly (ethylene glycol) molecular weight and 
microparticle size on oral insulin delivery from P(MAA-g-EG) microparticles, 
Drug Dev. Ind. Pharm., 30:497-504, 2004. 
12. Mikos AG, Mathiowitz E, Langer R, and Peppas NA, Interaction Of Polymer 
Microspheres With Mucin Gels As A Means Of Characterizing Polymer 
Retention On Mucus, J. Colloid Interface Sci., 143:366-373, 1991. 
 52
13. Peppas NA, Devices based on intelligent biopolymers for oral protein delivery, 
Int. J. Pharm., 277:11-17, 2004. 
14. Podual K, Doyle FJ, and Peppas NA, Dynamic behavior of glucose oxidase-
containing microparticles of poly(ethylene glycol)-grafted cationic hydrogels in 
an environment of changing pH, Biomaterials, 21:1439-1450, 2000. 
15. Yan XL and Gemeinhart RA, Cisplatin delivery from poly(acrylic acid-co-methyl 
methacrylate) microparticles, J. Control. Release, 106:198-208, 2005. 
16. Zhang J and Peppas NA, Structure and Solute Size Exclusion of Poly(N-
isopropylamide)/Poly(methacrylic acid) Interpenetrating Polymeric Networks, 
Polym. Prepr., 39:228-229, 1998. 
17. Zhang J and Peppas NA, Molecular interactions in poly(methacrylic 
acid)/Poly(N-isopropyl acrylamide) interpenetrating polymer networks, J. Appl. 
Polym. Sci., 82:1077-1082, 2001. 
18. Zhang J and Peppas NA, Morphology of poly(methacrylic acid)/poly(N-isopropyl 
acrylamide) interpenetrating polymeric networks, J. Biomater. Sci.-Polym. Ed., 
13:511-525, 2002. 
19. Hubbell JA, Biomaterials In Tissue Engineering, Bio-Technology, 13:565-576, 
1995. 
20. Lee JW, Park JH, and Robinson JR, Bioadhesive-based dosage forms: The next 
generation, J. Pharm. Sci., 89:850-866, 2000. 
21. Mathiowitz E, Chickering DE, and Lehr CM, Bioadhesive Drug Delivery 
Systems:  Fundamentals, Novel Approaches, and Development. 1999, New York, 
NY: Marcel Dekker, Inc. 
22. Peppas NA and Buri PA, Surface, Interfacial and Molecular Aspects of Polymer 
Bioadhesion on Soft Tissues, J. Control. Release, 2:257-275, 1985. 
23. Peppas NA and Sahlin JJ, Hydrogels as mucoadhesive and bioadhesive materials: 
A review, Biomaterials, 17:1553-1561, 1996. 
24. Smart JD, The basics and underlying mechanisms of mucoadhesion, Adv. Drug 
Deliv. Rev., 57:1556-1568, 2005. 
25. Achar L and Peppas NA, Preparation, Characterization And Mucoadhesive 
Interactions Of Poly(Methacrylic Acid) Copolymers With Rat Mucosa, J. 
Control. Release, 31:271-276, 1994. 
 53
26. Ende MTA and Peppas NA, Transport of ionizable drugs and proteins in 
crosslinked poly(acrylic acid) and poly(acrylic acid-co-2-hydroxyethyl 
methacrylate) hydrogels.2. Diffusion and release studies, J. Control. Release, 
48:47-56, 1997. 
27. Kim B, La Flamme K, and Peppas NA, Dynamic swelling Behavior of pH-
sensitive anionic hydrogels used for protein delivery, J. Appl. Polym. Sci., 
89:1606-1613, 2003. 
28. Peppas NA and Tennenhouse D, Semicrystalline poly(vinyl alcohol) films and 
their blends with poly(acrylic acid) and poly(ethylene glycol) for drug delivery 
applications, J. Drug Deliv. Sci. Technol., 14:291-297, 2004. 
29. Robinson DN and Peppas NA, Preparation and characterization of pH-responsive 
poly(methacrylic acid-g-ethylene glycol) nanospheres, Macromolecules, 35:3668-
3674, 2002. 
30. Torres-Lugo M and Peppas NA, Transmucosal delivery systems for calcitonin: a 
review, Biomaterials, 21:1191-1196, 2000. 
31. Dong J, Ozaki Y, and Nakashima K, Infrared, Raman, and near-infrared 
spectroscopic evidence for the coexistence of various hydrogen-bond forms in 
poly(acrylic acid), Macromolecules, 30:1111-1117, 1997. 
32. Lazzari M, Kitayama T, Hatada K, and Chiantore O, Effect of stereoregularity on 
the thermal behavior of poly(methacrylic acid)s. 2. Decomposition at low 
temperatures, Macromolecules, 31:8075-8082, 1998. 
33. Wang C, Tam KC, and Jenkins RD, Dissolution behavior of HASE polymers in 
the presence of salt: Potentiometric titration, isothermal titration calorimetry, and 
light scattering studies, J. Phys. Chem. B, 106:1195-1204, 2002. 
 54
Table 4.1 Composition of the P(M)AA microparticles prepared using a precipitation 
polymerization. 
monomer/crosslinking agent AA/APE MAA/PETA 
wt % initiator 0.5 0.5 
wt % monomer 10.0 10.0 
mol % crosslinking agent 0, 0.2, 0.43, 0.75, 1.46, 3.00 0, 0.43, 0.75, 1.46, 3.00 
mol % neutralized 3.1 3.1 





Figure 4.1 Molecular structures of (a) the carboxylic acid monomer (R1 = H for AA or 
R1 = CH3 for MAA), (b) the tri-functional pentaerythritol (R2 = CH for 



































































Figure 4.6   Glass transitions of crosslinked PMAA microparticles as a function of mol 
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Figure 4.7   Glass transitions of crosslinked PAA microparticles as a function of mol % 
crosslinking.  Each bar represents the mean ± SD (n=3).
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Figure 4.8 pH responsive equilibrium swelling behavior of crosslinked microparticles 
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Chapter 5:  Dynamics of Poly(ethylene glycol)-Tethered, pH Responsive 
Biomaterials 
INTRODUCTION 
Tethered polymer networks have received considerable attention for their use in 
modifying surface adhesion and friction (1-3), drug delivery systems (4-8), and 
bioadhesives (2, 3, 9, 10).  Biomimetic systems, biomaterials that mimic a biological 
environment to elicit a desired cellular response (11), have also utilized tethered 
macromolecules to effectively enhance cellular adhesion (12-14) or prevent protein 
adsorption (15).  Certain tethered polymer surfaces have been theorized to act as adhesion 
promoters by interpenetrating into the mucous gel layer, bridging the interface between 
the hydrogel-based drug delivery system and the absorption site (16). 
Hydrogels have been frequently used in biomedical applications because of the 
many shared characteristics with natural tissue.  The gel/gel adhesion between the 
hydrogel and the natural tissue can be controlled with the use of tethered polymers at the 
surface of the biomaterial.  Since hydrogels are porous penetrable materials much like 
natural tissue, the tethered layer along with the bulk structure of the polymer requires a 
fundamental understanding to evaluate the structure-property relationships and dynamics. 
Synthesis of polymer microparticles as the geometry for the hydrogel material is 
preferred due to their ease of incorporation into traditional dosage forms such as tablets 
and capsule formulations.  Drug-loaded microparticles can be used on their own as drug 
delivery systems due to their relatively high loading capacity and ease of administration.  
Thermally initiated free-radical precipitation polymerizations are typically utilized as the 
preparation technique for obtaining microparticles possessing the necessary 
compressibility characteristics needed for successful tablet compression (17). 
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The incorporation of an (meth)acrylic acid monomer possessing a carboxylic acid 
moiety imparts pH responsive behavior into the hydrogel network.  The anionic behavior 
of the polymer allows for ionic repulsion to occur along the polymer backbone, causing 
the hydrogel networks to expand and collapse depending on whether the pH of the 
environment is above or below the pKa of the polymer.  The addition of a polymer tether 
capable of participating in interpolymer complexation may affect the swelling behavior, 
mechanical properties, and solute transport characteristics dependent upon the state of the 
network, complexed or uncomplexed. 
Interpolymer complexation forms between electron deficient moieties, such as the 
carboxylic acid groups found along the backbone of polyacids, and moieties containing 
regions of high electron density, such as the ether groups comprising poly(ethylene 
glycol) (PEG).  The complexation behavior is a result of the non-covalent association 
between the polyacid and the tether as a result of hydrogen-bonding between the carboxyl 
group and the ether oxygen.  This interpolymer complexation is a thermodynamically 
favorable event and is reversible in nature.  The stability of the complex formed is 
strongly dependent on the structure of the polymers and their relative amounts 
incorporated into the network.   
For complexation to occur, the pH of the environment must be substantially lower 
than the pKa of the polyacid network to allow for sufficient protonation of the carboxylic 
acid group.  Upon approach to the pKa, deprotonation occurs, causing the network to 
decomplex.  Upon decomplexation, the dynamics of the network are significantly altered, 
allowing for increased swelling, a decrease in the mechanical intergrity of the network, 
and increased solute diffusion.  Due to these interesting characteristics, these polymer 
networks can be utilized in biosensing applications, molecular recognition, and drug 
delivery systems. 
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In our research, we focus on the synthesis and characterization of microparticles 
composed of polymers possessing the ability to form interpolymer complexes stabilized 
by hydrogen bonding.  These tethers are also present to act as adhesion promoters 
between the hydrogel and other gel networks such as the mucous gel layer covering the 
epithelium of the gastrointestinal tract.  The conditions necessary for a successful 
polymerization are elucidated.  The effects of the concentration and size of the polymer 
tether on the dynamics of the polymer networks are evaluated.  Also, the behavior of two 
different polyacids in conjunction with the polymer tether is studied.   
MATERIALS AND METHODS 
Materials 
Methacrylic acid (MAA, inhibited with 250 ppm hydroquinone), anhydrous 
potassium carbonate (K2CO3), and ethyl acetate (EtAc) were obtained from Fisher 
Scientific and used as received.  Acrylic acid (AA, inhibited with 200 ppm 
hydroquinone), poly(ethylene glycol) monomethyl ether monomethacrylate (PEGMMA, 
Mn ~ 300, 1100) and  PEGMMA solution (Mn ~ 2080, 50 wt % in H2O) was obtained 
from Sigma Aldrich (Milwaukee, WI).  The PEGMMA 50 wt % in H2O solution was 
freeze dried to obtain anhydrous PEGMMA Mn ~ 2080.  Allyl pentaerythritol (APE), 
pentaerythritol triacrylate (PETA), and di(4-tert-butylcyclohexyl) peroxydicarbonate 
(BCHPC) were kindly supplied by Perstorp Polyols (Toledo, OH), Sartomer (Exton, PA), 
and Degussa Initiators (Elyria, OH), respectively.  All other chemicals were of reagent 
grade and used as received. 
Synthesis 
In a typical thermally-initiated free radical precipitation polymerization, MAA,  
K2CO3, PEGMMA, and deionized distilled water (ddH2O) were combined and mixed to 
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form a homogeneous mixture, allowing the escape of the neutralization by-product 
carbon dioxide (17).  The crosslinking agent, APE or PETA, was dissolved in ethyl 
acetate.  The monomer mixture and crosslinking agent were added to a four-necked round 
bottom flask equipped with an overheard stirrer, nitrogen purge, and condenser 
containing the polymerization solvent EtAc.  Following a 20 minute purge with nitrogen, 
the initiator BCHPC dissolved in the polymerization solvent was added to the vessel and 
further purged for an additional 10 minutes.   
The molecular structures of the monomer, crosslinking agent, and thermal 
initiatior are shown in Figure 5.1.  The vessel was placed in a thermostatic bath at 50°C ± 
0.5°C where precipitation was evident in a matter of minutes.  The reaction was allowed 
to proceed for 16 hours to ensure a high percentage of monomer conversion.  Following 
the polymerization, the particle slurry was centrifuged and washed with fresh ethyl 
acetate and dried using a rotary evaporator at elevated temperature and reduced pressure 
(90°C/40 mmHg). 
Characterization 
Discs containing 1 mg of sample and 150 mg of KBr were prepared on a Carver 
laboratory press using a 15,000 lb compression force.  Infrared spectra of the 
microparticles were obtained in the wavenumber range of 400-4000 cm-1 on a Fourier 
transform infrared spectrophotometer (FT-IR, Thermo Mattson Infinity, Thermo Electron 
Corp., Waltham, MA) in transmission mode equipped with a KBr beamsplitter and 
DTGS detector.  Each spectrum is an average of 64 scans at a resolution of 1 cm-1.   
The thermal properties of the microparticles were characterized using a 
differential scanning calorimeter (DSC, MDSC 2920, TA Instruments, New Castle, DE).  
Approximately 10-15 mg samples were analyzed at a sample rate of 10°C/min over the 
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range of 80°C to 160°C for poly(acrylic acid) and 80°C to 300°C for poly(methacrylic 
acid) using a heat/cool/heat method to erase the thermal history.   
The equilibrium weight swelling ratio of the polymeric hydrogel microparticles 
was determined by carefully weighing 50 mg of dried particles and combining them with 
35 mL of NaHCO3 solution (1.5 g / 100 mL).  The suspension was agitated for 60 min 
and then centrifuged for 60 min at 2000 rpm, carefully discarding the supernatant.  The 
pellet was resuspended in an additional 35 mL of NaHCO3 solution and agitated for 60 
min.  The suspension was centrifuged at 2000 rpm for 60 min, carefully removing the 
supernatant, and the weight of the gelled mass was determined.  This procedure was also 
carried out in a 0.1 N HCl solution.   
Approximately 4.0 g of the prepared polymer microparticles previously dried at 
30°C and 28 inHg were added to 350 mL of an agitated aqueous solution containing the 
appropriate amount of NaCl to achieve the specified ionic strength.  After a 15 minute 
hydration period, the pH of the microparticle slurry was adjusted accordingly using 1 N 
NaOH, and a sufficient volume of ddH2O was added to make the final volume of liquid 
400 mL. 
One mL of the polymer gel was placed on the lower of the two cylindrical (D = 
19 mm) agarose sample mounts (0.5 g agarose in 50 mL of ddH2O) in a tensile tester 
(Instron 4301, 10 N load cell, Canton, MA) at 22°C.  The upper sample mount was 
brought into contact with a 42 mN impingement force achieved through resting the upper 
sample mount on the gel sample and lower sample mount, and the gel was allowed to 
relax for five minutes.  The upper sample mount was raised at 6 mm/min until failure of 
the gel bond occurred, and the detachment force was measured as a function of 
displacement.  The area under the curve of force versus length up until the peak force is 
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defined as the work of adhesion, and the area post peak force is defined as the work of 
cohesion. 
RESULTS AND DISCUSSION 
Precipitation  Polymerization  for  Synthesis  of  Tethered  Microparticles 
The main requirements for a precipitation polymerization are the presence of an 
inert diluent which dissolves the monomer but precipitates the polymer as it is formed.  In 
the formation of the tethered microparticles, the monomer, crosslinking agent, tether, and 
initiator are dissolved in ethyl acetate which is a non-solvent for the formed polymer 
(18).  Polymer precipitates out and forms agglomerated microparticles as it is formed.  
These types of polymerizations are different than those of dispersion polymerizations in 
that there is no polymeric dispersant present to stabilize the polymer particles as they are 
formed.  This stabilizer forms a dissolved protective layer around the polymer particles as 
they grow, and its absence presents an unstable dispersion which results in flocculation of 
the growing polymeric particles.  The resultant microparticle is composed of primary 
polymeric particles which have agglomerated together. 
The processes involved with precipitation polymerizations depend on the 
solubility characteristics of the polymer, especially those processes related to the 
formation and growth of polymer particles.  The free energy change ∆Gm must be 
negative for the monomers and the diluent to mix.  More specifically the heat of mixing 
∆Hm must be smaller than the entropy factor T∆Sm since the entropy of mixing will 
always be positive as can be seen in equation (5.1). 
mmm STHG ∆−∆=∆        (5.1) 
The total cohesion energy, the total energy needed to separate the molecules of 
each liquid to a distance infinitely far from one antother, is given by equation (5.2). 
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mv VRTHE /)( −∆=         (5.2) 
The solubility parameter δ is defined as the square root of the cohesive energy 
density since the interaction between the unlike molecules can be taken as the geometric 
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The heat of mixing can be obtained by subtracting the contributions of a mixture 
from the cohesive energies of the separate unmixed components as shown in equation 
(5.4) where Vm is the average molar volume of the mixture.  Because the interactions 





112211 φφφφφφ EEEEEVH mm ++−+=∆    (5.4) 
From these equations, the heat of mixing can be expressed in the following form 
and is minimized when the difference between the solubility parameters of the liquids are 
as small as possible. 
2
2121 )( δδφφ −=∆ mm VH        (5.5) 
Flory-Huggins solution theory shows that the free energy of mixing (5.6) is highly 
dependent on the molecular weight of the polymer. 
( ) ( )( )212211 ln)/(ln/ φχφφφφφ ++=∆ mVRTG vm     (5.6) 
χ is the Flory polymer-solvent interaction parameter which is related to the 
solubility parameters of the components by equation, where β is a correction to the Flory 
combinatorial entropy with a value between 0.2-0.4. 
RTV /)( 1
2
21 δδβχ −+=        (5.7) 
Further evaluation of precipitation and phase separation can be described as an 
equilibrium process by the Flory-Huggins theory and one can derive the chemical 
potential for each component of the precipitation polymerization.  These deriviations 
yield that the solubility of a polymer in a liquid diluent falls off very rapidly as the 
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molecular weight is increased and as the difference in solubility parameters for each 
component increases (18). 
The precipitation polymerization of tethered microparticles synthesized in this 
work occurs through the following stages:  (a) the polymer formed is insoluble in the 
diluent and polymer particles precipitate from the initially homogeneous reaction 
solution; (b) opalescence is detected almost immediately after initiation of polymerization 
due to the formation of polymer particles at very low conversions; (c) high molecular 
weight polymers are obtained due to restricted radical termination in the formed glassy 
particle (19). 
Due to the application of the particles in drug delivery systems, the absence of a 
dispersant was desired to eliminate the need for removal.  The resulting size distribution 
is rather polydisperse with 95% of the particles being smaller than 30 µm (data not 
shown).  The addition of the low molecular weight PEG used in these studies did not act 
as a polymerizable stabilizer as can be noted from the presence of the agglomeration and 
the absence of individual primary particles. 
For AA precipitation polymerizations, it is necessary to preneutralize a small 
portion of the acrylic acid monomers to form potassium acrylate.  Potassium acrylate 
imparts the proper solubility characteristics onto the formed polymer to precipate out of 
solution.  Without the addition of potassium acrylate to the monomer solution, 
polymerization and marginal precipitation occurs, but the large agglomerates formed are 
undesirable.  The polymerization proceeds as a solution polymerization without 
production of any microparticles.  For PMAA, the preneutralization is not necessary due 
to the solubility characteristics of the formed polymer, but can be utilized to increase the 
microclimate pH of the particles formed.  However, a large concentration of potassium 
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acrylates and methacrylates is insoluble in ethyl acetate, resulting in a heterogeneous 
monomer/diluent mixture. 
For the P(AA-g-PEG) polymerizations, the PEG does affect the solubility of the 
formed microparticles.  With PEG being soluble in ethyl acetate, its incorporation results 
in a higher propensity for salvation of the growing polymer chains.  This effect can be 
kinetically controlled by decreasing the reaction temperature after initiation to decrease 
the extent of agglomeration that occurs.  For P(MAA-g-PEG) polymerizations, this effect 
is negligible due to large extent of the insolubility of PMAA in ethyl acetate. 
The choice of initiator relies on the fact that a lower reaction temperature is 
needed for increasing concentrations of PEG.  The peroxydicarbonate provides this 
element, however, lauroyl peroxide can also be utilized as the initiator for systems 
composed of a high AA:EG ratio or for all MAA systems.  The choice of crosslinking 
agent is also dependent on the monomer employed.  Due to the reactivity ratios of acrylic 
and methacrylic acid, an allyl or acrylate functionalized crosslinking agent, respectively, 
must be used to achieve a crosslinked network. 
FT-IR Spectroscopy of Poly(ethylene glycol)-tethered Biomaterials 
Figures 5.2 through 5.8 show the IR spectra for crosslinked poly(acrylic acid) 
(PAA) microparticles containing the PEGMMA tether at various concentrations and 
potassium acrylate (P(AA-g-PEG)) and Table 5.1 lists the vibrational assignments for the 
various peaks present in the spectra.  All spectra exhibit the characteristic C=O 
stretching, with crosslinked PAA stretching occurring at 1710 cm-1 and moving to a 
slightly higher wavenumber with increasing PEG tether concentration (1740 cm-1 for 
AA:EG 50:50).  This indicates a higher prevalence of obtaining cyclic hydrogen-bonded 
COOH groups in dimeric form with a decreasing concentration of the PEG tether (20).  
As the concentration of PEG increases in the network, free (non-hydrogen-bonded) 
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COOH groups increases due to the disruption or prevention of dimeric formation with the 
addition of the PEG macromolecule into the structure.  The asymmetric vibration of the 
methyl group present at the end of the PEG tether is exhibited on the FT-IR spectrum at 
approximately 2890 cm-1.  The characteristic C-O-C stretching of the PEG tether is 
clearly evident at approximately 1110 cm-1. 
Differential Scanning Calorimetry 
The glass transtition temperature, Tg, of the dry crosslinked PAA is approximately 
131°C, which is significantly higher than that reported for linear PAA.  As reported 
previously (17), this can be attributed to the presence of the pentaerythritol crosslinking 
agent and potassium acrylate.  Upon incorporation of small amounts of the PEG tether 
(AA:EG 98:2 and 90:10), the ∆Cp is decreased with no change or appearance of a second 
Tg observed.  It is not until the ratio of AA:EG is increased to 83:17 that a second Tg is 
observed.  This is due to a heterogeneous network consisting of crosslinked PAA rich 
domains and domains containing both crosslinked PAA and the PEG tether.  Upon 
further increase of the PEG concentration, a single lower Tg is observed, indicating the 
return to a more homogenous network. 
Swelling Behavior of PEG-tethered Hydrogel Networks 
To evaluate the swelling properties of the PEG-tethered hydrogel networks, the 
amount of water uptake of the microparticles, q, was calculated according to equation 






q =         (5.8) 
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The polymer volume fraction after equilibrium swelling, υ2,s, was calculated 
according to equation (5.9), where ρd and ρwater are the density of the polymer (1.41 












=,2        (5.9) 
The average molecular weight between crosslinks, cM  , was calculated 
according to the Flory-Rehner equation, (5.10), where nM  is the number average 
molecular weight of the uncrosslinked polymer (20,000 for PMAA, 50,000 for PAA),  υ  
is the specific volume of the polymer (0.71 cm3/g), V1 is the molar volume of the 
swelling medium (18.1 cm3/mol), and χ is the Flory polymer-solvent interaction 
parameter in water which is calculated as a weighted average for the values PMAA, χ = 































    (5.10) 
After determining cM , the number of links between two crosslinks, n  , was 
calculated according to equation (5.11), where Mr is the average molecular weight of the 







=         (5.11) 
The value of the root mean squared end-to-end distance of the polymer chain in 
the freely jointed state was calculated using equation (5.12), where l   is the carbon-
carbon bond length (1.54 Å). 
( ) nr l=2/12         (5.12) 
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The root mean squared end-to-end distance of the polymer chain in the 
unperturbed state was calculated according to equation (5.6) where Cn is the Flory 
characteristic ratio or rigidity factor of the polymer (PMAA, Cn = 14.6, PAA, Cn = 14.6 , 
and PEG, Cn = 3.8). 
( ) 2/122/12 rCr no =        (5.13) 
Lastly, the mesh size of the hydrogel network, ξ, was determined according to 
equation (5.14). 
( ) 2/123/1,2 os r−=υξ        (5.14) 
The results for the swelling dynamics of PAA microparticles can be found in 
Table 5.2.  Loosely crosslinked PAA (0.43 mol % APE) imbibes a significant amount of 
water in the sodium carbonate buffer (pH~9) as compared to 0.1 N HCl.  As the amount 
of crosslinking agent increases, the degree of swelling in the carbonate buffer decreases.  
The results for the swelling dynamics of PMAA microparticles (Table 5.3) show a similar 
trend.  At similar crosslinking levels, PMAA microparticles imbibe a significantly lower 
amount of water due to the presence of the methyl group along the backbone of the 
polyacid.  Swelling for both networks occurs due to deprotonation of the carboxyl group 
resulting in ionic repulsion of the neighboring chains.  This causes the network to expand 
and imbibe more water.  In the 0.1 N HCl buffer, the carboxylic acid groups remain 
protonated and water uptake is minimal.  This expansion is also evident through the 
significant increase in the mesh size for the polymers in the carbonate buffer as compared 
to the 0.1 N HCl solution.  As crosslinking is increased, the mesh size decreases which 
corresponds to the lower solution uptake. 
Upon incorporation of PEG, the swelling dynamics of the PMAA microparticles 
changes significantly (Table 5.4).  The swelling capacity of the tethered hydrogels is 
significantly lower as compared to crosslinked PMAA microparticles containing no 
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tether.  The degree of swelling is similar with a slightly smaller mesh size.  The ratio of 
the mesh size in carbonate buffer versus 0.1 N HCl is significantly greater for tethered 
hydrogels.  This allows for a dramatic increase in the amount of water uptake in higher 
pH solutions compared with lower pH. 
Gel/Gel Adhesion of Tethered Hydrogels 
Crosslinked PAA hydrogel microparticles, upon neutralization, produce a highly 
viscous suspension at low concentrations (1 wt % polymer).  This viscous gel suspension 
possesses tack which is capable of adhering to other hydrogel materials.  This 
characteristic is exhibited in Figure 5.16 for crosslinked PAA microparticles containing a 
PEG tether.  The gel adhesion remains relatively unchanged upon incorporation of low 
amounts of the PEG tether (AA:EG 83:17).  However, as the concentration is increased to 
a ratio of AA:EG 60:40, a significant decrease in the adhesive characteristics is obtained.  
The viscosity of the neutralized hydrated gel is the key factor that contributes to the 
ability of the gel to act as a bioadhesive.  With higher concentrations of PEG, the amount 
of ionizable gropus present in the network are decreased which leads to a significant 
reduction in the viscosity of the gel.  The lowered viscosity in turn causes the adhesive 
characteristics to be lower than hydrogels containing lowered amounts of PEG. 
CONCLUSIONS 
The fundamental understanding of the behavior of tethered gel networks has 
implications in tissue engineering, adhesion, and drug delivery.  In this research, 
ionizable hydrogel networks containing a PEG tether were successfully synthesized using 
a thermally initiated free radical precipitation polymerization.  The effects of the PEG 
tether on the structure of the microparticles were evaluated.  The addition of the PEG was 
shown to cause disruption of the dimer formation of PAA.  Differential scanning 
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calorimetry exhibited a concentration dependent decrease in the Tg of xerogels.  At low 
concentrations, the network exhibits a heterogeneous behavior which is evident through a 
lowered ∆ Cp and the presence of two distinct Tg’s.   
The gel adhesion of a neutralized gel was shown to be dependent on the amount 
of PEG incorporated into the network, which in turn affected the viscosity of the gel.  
These materials possess interesting swelling properties which can be beneficial in the 
development of pH responsive drug delivery systems. 
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Table 5.1 Vibrational assignments for crosslinked PAA and the effect of PEG tether 
addition on the spectra of P(AA-g-PEG) microparticles. 
 
Wavenumber (cm-1) Intensity1 Assignment2 
    
x-PAA P(AA-g-PEG)   
    
3440  v υ (O-H) free groups 
~3200  m υ (O-H) associated w/ water 
2970  w υa (C-H) CH2 
 2890 m-s υa (CH3) 
~2620  w υ (O-H) bonded groups 
1710 shifts to slightly higher s υ (C=O) 
1560  s υ carboxylate ion 
1460 1460 w δ (CH2) out of plane 
1260  s υ (C=O) or δ (O-H) 
1190  s related to 1260 
 1110 s υ (C-O-C) 
820  w γ (CH2) 
 
1Intensity:  v, variable; w, weak; m, medium; s, strong.  2Vibrations:  υ, stretching; a, 
asymmetric; δ, bending; γ, rocking.  
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Table 5.2 Equilibrium swelling ratio of crosslinked PAA microparticles. 
 











Mesh Size   
(ξ, Å) 
0.0043 17.0 ± 0.3 420 91.4 ± 0.8 780 
     
0.0075 15.0 ± 0.2 400 64.6 ± 1.7 700 
     
0.0148 14.4 ± 0.2 390 47.6 ± 0.2 630 
     
0.0309 16.5 ± 0.7 420 34.7 ± 2.2 561 
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Table 5.3 Equilibrium swelling ratio of crosslinked PMAA microparticles. 
 












Mesh Size   (ξ, 
Å) 
0.0043 11.6 ± 0.6 270 40.5 ± 0.4 350 
     
0.0079 11.9 ± 0.5 270 34.8 ± 0.8 340 
     
0.0148 11.8 ± 0.6 270 26.6 ± 0.6 310 
     
0.0309 11.2 ± 0.7 260 20.8 ± 1.1 290 
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Table 5.4 Equilibrium swelling of crosslinked PEG-tethered PMAA microparticles 
(PEG-1000). 
 










Mesh Size   (ξ, 
Å) 
83:17 6.1 ± 0.2 61 41.6 ± 0.9 300 
     
69:31 5.8 ± 0.3  54 42.0 ± 0.5 290 
     





Figure 5.1 Molecular structures of (a) the carboxylic acid-containing monomer (R1 = H 
for AA or R1 = CH3 for MAA), (b) a poly(ethylene glycol) tether (z ~ 5, 23, 
and 45), (c) the tri-functional pentaerythritol (R2 = CH for APE or R2 = 

















































Figure 5.2 FT-IR spectrum of crosslinked PAA (0.75 mol % APE) showing the 
characteristic carbonyl stretching and fingerprint for the molecular structure 












Figure 5.3 FT-IR spectrum of P(AA-g-PEG), PEG-1000, AA:EG 98:2, exhibiting the 












Figure 5.4 FT-IR spectrum of P(AA-g-PEG), PEG-1000, AA:EG 90:10, exhibiting the 












Figure 5.5 FT-IR spectrum of P(AA-g-PEG), PEG-1000, AA:EG 83:17, exhibiting the 












Figure 5.6 FT-IR spectrum of P(AA-g-PEG), PEG-1000, AA:EG 60:40, exhibiting the 













Figure 5.7 FT-IR spectrum of P(AA-g-PEG), PEG-1000, AA:EG 50:50, exhibiting the 












Figure 5.8 FT-IR spectrum of (a) crosslinked PAA (0.75 mol % APE), (b) P(AA-g-



















Figure 5.9 DSC thermogram of crosslinked PAA (0.75 mol % APE) exhibiting a Tg at 
131°C. 














Figure 5.10 DSC thermogram P(AA-g-PEG), PEG-1000, AA:EG 98:2, exhibiting a Tg 
at 131°C. 













Figure 5.11 DSC thermogram of P(AA-g-PEG), PEG-1000, AA:EG 90:10, exhibiting a 
Tg at 130°C. 














Figure 5.12 DSC thermogram of P(AA-g-PEG), PEG-1000, AA:EG 83:17, exhibiting 
two Tg’s at 130°C and 94°C. 















Figure 5.13 DSC thermogram of P(AA-g-PEG), PEG-1000, AA:EG 60:40, exhibiting a 
Tg at 68°C. 













Figure 5.14 DSC thermogram of P(AA-g-PEG), PEG-1000, AA:EG 50:50, exhibiting a 
Tg at 61°C. 














Figure 5.15 DSC thermogram of (a) crosslinked PAA (0.75 mol % APE), (b) PAA 
P(AA-g-PEG), PEG-1000, AA:EG 98:2, (c) 90:10, (d) 83:17, (e) 60:40, (f) 
50:50. 


























Figure 5.16 Evaluation of the peak force obtained from neutralized hydrated gels 
containing (a) crosslinked PAA (0.75 mol % APE), (b) P(AA-g-PEG), PEG-




















Figure 5.17 Evaluation of the work of adhesion of neutralized hydrated gels containing 
(a) crosslinked PAA (0.75 mol % APE), (b) P(AA-g-PEG), PEG-1000, 






















Figure 5.18 Evaluation of the work of cohesion of neutralized hydrated gels containing 
(a) crosslinked PAA (0.75 mol % APE), (b) P(AA-g-PEG), PEG-1000, 























Chapter 6:  Oral Minitablet Drug Delivery Matrices Containing 
Poly(ethylene glycol) Tethered, pH Responsive Excipients 
INTRODUCTION 
Mucoadhesive controlled drug delivery systems have the ability to maintain a 
controlled rate of release of the drug while localizing the drug at a specific absorption 
site.  Both controlling release and localizing the drug concentration results in a prolonged 
duration of action and increased bioavailability.  A mucous gel layer covers the hollow 
cavities of the body which include the buccal, nasal, gastrointestinal, and the urogenital 
paths.  The gastrointestinal or oral delivery of therapeutics is the most preferred route of 
administration due to the higher patient compliance and ease of administration.  
Therefore, the development of controlled release drug delivery systems that are 
mucoadhesive has the potential to be effective at increasing the bioavailability of 
formulations in which efficacy has been difficult to achieve. 
Challenges for the oral delivery of small and large molecular mass drugs include 
the harsh acidic environment of the stomach, the presence of degradative enzymes, and 
the narrow absorption window (low residence time) for certain compounds.  To combat 
these effects, a drug delivery system that prevents denaturation or degradation and 
increases the residence time can increase the bioavailabilty of these problem ridden 
compounds.  Carriers based on polyacid poly(ethylene glycol)-tethered complexation 
hydrogels have the capacity to overcome these formulation issues. 
Mucoadhesive polymer-based drug delivery systems were first utilized by Nagai 
and collaborators as carriers for local treatment to the buccal cavity (1, 2).  Mucus is also 
present in the nasal and gastrointestinal cavity, the vagina, and other hollow organs, 
providing a diverse arena for the application of mucoadhesive drug delivery systems. 
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Polymers that have typically been utilized in the development of mucoadhesive 
controlled release formulations include hydrophilic macromolecules containing numerous 
hydrogen bonding groups such as poly((meth)acrylic acid) which include the carbomer 
and polycarbophil families (Figure 2.3), cellulosics, and (semi)natural ones such as 
chitosan and alginate (3).  Like so many other materials that were first utilized in 
biomedical applications (cellulous acetate dialysis tubing, Dacron® vascular grafts, and 
polyurethane heart molds), these materials were available off-the-shelf.  Because their 
use was originally intended for other applications and was only transitioned into oral drug 
delivery systems, the drug delivery systems comprised of these materials have been 
classified as the first generation bioadhesive-based dosage forms (4).   
Poly(acrylic acids) have been widely utilized for mucoadhesive applications due 
to their ability to form strong bonds with tissues and maintain a therapeutic at the desired 
site of administration for extended periods of time.  Their polyelectrolytic behavior 
imparts a pH responsive behavior into the hydrogel network due to the ionization of the 
acrylic acid units and repulsion of the neighboring polymeric chains.  This pH responsive 
behavior inhibits drug diffusion out of the matrix at a low pH (such as in the stomach) 
and allows drug release at a higher pH (such as in the small intestine).  This delayed 
release prevents drug degradation and denaturation that would occur otherwise.  
Poly(acrylic acids) have also been shown to bind calcium which renders degradative 
enzymes such as trypsin ineffective.  This effect further prevents the rapid degradation of 
therapeutic proteins and peptides. 
The incorporation of poly(ethylene glycol) (PEG) tethers into the polymer 
network provides interpolymer complexes due to the association between the etheric 
oxygen on the PEG backbone and the carboxyl group of the polyacid.  This complexation 
provides a more effective drug diffusion barrier at low pH’s (stomach), allowing for more 
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protection of the labile drug and enhanced pH responsive delivery.  The addition of PEG 
has been shown to act as an adhesion promoter, increasing the adhesion capacity of 
polymer networks containing the PEG tether (4). 
The mucous gel network serves as a target for mucoadhesive biomaterials 
composed of polymer chains with the ability to interpenetrate and bridge the interface 
between the drug carrier and the mucus (5, 6).  Polymer chains available at the surface of 
the biomaterial are often employed to serve as adhesion promoters (7-10).  With the 
polymer chains at the periphery of the delivery system, these polymer chains are able to 
develop an intimate contact with the mucous gel layer, diffuse across the interface, and 
form entanglements with the mucous gel layer.  Once the chains are across the 
polymer/gel boundary, further non-covalent mechanisms can occur to strengthen the 
bond.  The enhanced bridging is a result of further chain entanglement, secondary 
bonding, or electrostatic interactions.  For further enhancement of the adhesive bond 
formed between a delivery system and the mucous gel layer, tethered polymers, both 
anionic and cationic, can be used to create a synergistic effect in developing a more 
effective mucoadhesive delivery system (11-14). 
The theory surrounding polymers attached to hydrogels was further developed in 
our laboratory by Huang et al. (13, 14) who studied systems composed of two hydrogels 
involved with the process of mucoadhesion.  This theoretical framework provided 
evidence of the probability of finding both the chains and the free end segment outside 
the base gel available for interpenetration.  Both were dependent on the surface coverage 
of the polymer tethers, with a large number of the chains and free ends present outside 
the base gel at low and intermediate coverage.  However, at high coverages the chains 
penetrated back into the base gel due to the intermolecular interactions between 
neighboring chains.  Adhesion enhancement associated with the base and target gel 
 104
(mucus layer) was also shown to be maximized at an intermediate coverage.  Therefore, 
in designing biomaterials for mucoadhesive applications, the surface coverage of grafted 
polymer chains can be controlled to achieve adhesion enhancement through polymer-gel 
interpenetration (4). 
The objectives of this research were to synthesize PEG-tethered pH responsive 
biomaterials composed of polyacids, formulate these polymers into minitablet oral drug 
delivery matrices, and evaluate the ability of the polymer to act as a pH responsive 
controlled release excipients. 
MATERIALS AND METHODS 
Materials 
Methacrylic acid (MAA, inhibited with 250 ppm hydroquinone), anhydrous 
potassium carbonate (K2CO3), and ethyl acetate (EtAc) were obtained from Fisher 
Scientific and used as received.  Acrylic acid (AA, inhibited with 200 ppm 
hydroquinone) was obtained from Sigma Aldrich (Milwaukee, WI) and was used as 
received.  Allyl pentaerythritol (APE), pentaerythritol triacrylate (PETA), and di(4-tert-
butylcyclohexyl) peroxydicarbonate (BCHPC) were kindly supplied by Perstorp Polyols 
(Toledo, OH), Sartomer (Exton, PA), and Degussa Initiators (Elyria, OH), respectively.  
Poly(ethylene glycol) monomethyl ether monomethacrylate with a molecular weight of 
300, 1100, 2100 (PEGMMA-300, 1100, 2100) were obtained from Sigma Aldrich 
(Milwaukee, WI).  The 300 and 1100 molecular weights were used as received.  
PEGMMA-2100 was freeze dried to remove the water (commercially available as a 50 % 
w/w solution in water).  Anhydrous lactose, magnesium stearate, and theophylline were 
purchased from Spectrum Chemical (Pasadena, CA). Carbopol 971P NF and Carbopol 
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974P NF were donated by Noveon (Cleveland, OH).  All other chemicals were of reagent 
grade and used as received. 
Synthesis 
The synthesis of the microparticles utilized in the dosage forms has been 
described previously (15, 16).  Briefly, in a typical thermally-initiated free radical 
precipitation polymerization, (M)AA,  K2CO3, PEGMMA, and deionized distilled water 
(ddH2O) were combined and mixed to form a homogeneous mixture, allowing the escape 
of the neutralization by-product carbon dioxide.  The crosslinking agent, APE or PETA, 
was dissolved in ethyl acetate.  The monomer mixture and crosslinking agent were added 
to a four-necked round bottom flask equipped with an overheard stirrer, nitrogen purge, 
and condenser containing the polymerization solvent EtAc.  Following a 20 minute purge 
with nitrogen, the initiator BCHPC dissolved in the polymerization solvent was added to 
the vessel and further purged for an additional 10 minutes.   
The vessel was placed in a thermostatic bath at 50°C where precipitation was 
evident in a matter of minutes.  The reaction was allowed to proceed for 16 hours to 
ensure a high percentage of monomer conversion.  Following the polymerization, the 
particle slurry was centrifuged and washed with fresh ethyl acetate and dried using a 
rotary evaporator at elevated temperature and reduced pressure (90°C/40 mmHg).  Table 
1 lists the various polymer microparticles prepared. 
Preparation of Tablet Matrices 
The tablets were prepared according to the formulation listed in Table 6.1.  All 
components were sieved prior to preparation.  The multifunctional polymer, theophylline, 
and anhydrous lactose were mixed in a mortar and pestle.  The magnesium stearate and 
Cab-O-Sil were combined with this mixture and further mixed until a homogeneous 
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mixture was obtained.  An 80 mg portion of the sample mixture was compressed using a 
hydraulic compactor (Fred S. Carver Inc., Menomonee Falls, WI) at a pressure of 2000 
kg. 
Dissolution of Tablet Matrices 
The drug-release properties of the matrix tablets were evaluated according to 
United States Pharmacopeia (USP) 27 apparatus 2 at 50 rpm and 37°C, using a 
dissolution system (Distek Dissolution System 2100B, North Brunswick, NJ).  For 
diffusional analysis, tablets were placed in either 750 mL of 0.1 N HCl or 750 mL of 0.1 
N HCl and 250 mL 0.2 M Na3PO4 (pH of the respective buffers being ~ 1 and 6.8), and 5 
mL samples were removed.  A final sample was withdrawn at 24 hours to represent the 
amount released at time infinity.  To evaluate the pH responsive behavior of the matrices, 
a modified USP enteric test was performed.  Briefly, the tablets were first placed in 750 
mL of 0.1 N HCl for one hour and 5 mL samples were withdrawn.  At the end of the hour 
time period, 0.1 N HCl buffer was added to replace the withdrawn volume, and 250 mL 
of 0.2 M Na3PO4 buffer was added to the vessel to increase the pH to 6.8.  Samples were 
withdrawn, with the time infinity sample withdrawn at 24 hours. 
Dissolution samples were analyzed using a Bio-Tek® Synergy HT 96-well plate 
ultraviolet/visbible (UV/Vis) spectrophotometer at a wavelength of 272 nm, 
corresponding to the peak absorbance for theophylline. 
RESULTS AND DISCUSSION 
Most drug delivery systems composed of a release rate controlling polymer can be 
described by the following two forms of Fick’s law of diffusion, where ci and ji are the 
concentration and mass flux of drug i, respectively; x and t are position and time of 
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The solution to equation (6.2) provides the time-dependent release of the matrix 
containing the rate controlling polymer.  In matrix systems, the drug is incorporated in 
the polymer by physically mixing the compound with the polymer and other excipients.  
The solubility of the drug becomes a controlling factor in the modeling of the release 
depending on whether or not the initial drug loading is above or below the solubility 
limit.  For the cases represented in this study, the initial loading was below the solubility 
limit, allowing for simple molecular diffusion of the drug through the polymer. 
The systems investigated in this research were matrix tablets that were uniformly 
loaded at an initial concentration, ci,o  When the surface concentration of the drug in the 
dissolution medium is kept constant, i.e. sink conditions, and for small release times 






























   (6.3) 
Equation (6.3) can be further simplified to the form used in this work to describe the 













M ipt        (6.4) 
The fractional release of a compound in a slab drug delivery system is clearly 
proportional to the t1/2 for early times.  For systems possessing a lag time before release 
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occurs, an additional term, θ, is amended to equation (6.4) to account for this time where 















M ipt        (6.5) 
Poly(acrylic acid)-containing Minitablets 
Figure 6.2 and 6.3 show the release profile for dissolution studies of PAA tablets 
in 0.1 N HCl and pH 6.8 buffer, respectively.  As PAA is soluble in both the acidic and 
near-neutral solutions, the polymer dissolves at the surface of the tablet.  Dissolution is 
not as rapid in the acidic environment, and the matrix slightly swells under these 
conditions due to the hydrophilic nature of the polymer.  In the pH 6.8 buffer, ionization 
of the PAA polymer occurs and polymer dissolution is more rapid, which results in a 
slightly higher effective diffusion coefficient, Deff , for the model compound. 
Table 6.2 displays the results of the diffusional analysis of novel mintiablet 
matrices composed of poly(acrylic acid) (PAA) microparticles.  Upon incorporation of a 
small amount of crosslinking agent (0.2, 0.43, and 0.75 mol % APE), the calculated 
value, Deff was significantly decreased in both dissolution media.  In the low pH 
environment, the matrices swell due to the hydrophilic nature of the polymer carrier 
which increases the porosity of the tablet allowing for a slightly higher Deff than in the pH 
6.8 buffer.  Due to the pH responsive nature of the polymers in the tablets causing 
ionization and swelling, a gel layer is formed at the surface of the tablet for the loosely 
crosslinked polymers (0.2 and 0.43 mol % APE and Carbopols) which acts as a diffusion 
inhibiting layer.  For the more densely crosslinked particles, the release behavior in the 
acidic buffer dissolution media is similar to that of linear PAA.  In the pH 6.8 buffer, the 
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individual particles at the periphery of the tablet swell and are released, resulting in 
significantly higher Deff for the model compound. 
Poly(methacrylic acid)-containing Minitablets 
Figures 6.4 and 6.5 show the release profile of theophylline from these tablets. 
Table 6.3 displays the results for the diffusional analysis of poly(methacrylic acid)-
containing (PMAA) tablets.  PMAA is more hydrophobic than PAA due to the presence 
of the methyl group.  In the low pH environment, the PMAA tablets only slightly swell 
and polymer dissolution is negligible during the time scale of these experiments.  
However, in the higher pH environment, ionization occurs and a dissolving gel layer of 
polymer is formed. 
The trend is similar for tablets containing crosslinked PMAA.  The slight polymer 
swelling induces an increase in the porosity of the tablets resulting in an affected Deff.  At 
the higher pH, loosely crosslinked polymers behave similarly to linear PMAA.  With 
increased crosslinking, swollen particle release from the surface of the tablet is more 
prevalent. 
Minitablets composed of PEG-tethered PAA Microparticles 
The release profile of theophylline from these systems can be observed in Figure 
6.6 and 6.7.  The release behavior for tablets containing a low concentration of PEG is 
similar to that obtained for PAA systems.  The effect of the PEG tether is not 
significantly evident until a 50:50 AA:EG ratio for PEG-300 and 70:30 AA:EG for PEG-
2000.  Release is inhibited in the 0.1 N HCl media due to the complexation of the etheric 
oxygens and the carboxyl groups present on the PAA backbone.  In the pH 6.8 buffer, 
interpolymer decomplexation occurs, resulting in an increase in the porosity of the tablet 
and, subsequently, the release of the theophylline.  Table 6.4 displays the results for the 
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diffusional analysis for the release of theophylline from mintablets composed of 
poly(ethylene glycol)-tethered (PEG) PAA.   
Minitablets Composed of PEG-tethered PMAA Microparticles 
The release profile for these systems in either 0.1 N HCl or pH 6.8 buffer can be 
observed in Figures 6.8 and 6.9, respectively.  The result of the diffusional analysis for 
minitablets containing PEG-tethered PMAA microparticles is exhibited in Table 6.5.  
Due to interpolymer complexation, which causes a lower degree of swelling and 
expansion of the minitablet, the Deff for these tablets is significantly lower in the low pH 
environment.  Upon introduction to a higher pH environment, decomplexation occurs 
allowing for the matrix to open up and release the drug.  However, for relatively large 
amounts of PEG (MAA:EG 50:50), release is significantly inhibited at both pH’s.  The 
reason for inhibition at higher pH’s is due to the slower dynamics of the decomplexation 
which can be attributed to decreased penetrant diffusion.  Less water is uptaken by the 
minitablet, which results in slower decomplexation dynamics and a lowered Deff  for 
theophylline. 
CONCLUSIONS 
Novel oral minitablet drug delivery matrices were successfully formulated using 
pH responsive hydrogel microparticles.  The release of a model drug was shown to be 
dependent on the amount of crosslinking agent incorporated during microparticle 
synthesis with lower degrees of crosslinking being preferred for effective release 
characteristics.  The amount of PEG was shown to significantly alter the release behavior 
due to interpolymer complexation between the ether oxygens and the carboxylic acid 
groups.  The release behavior was modeled according to a simplified model for 
monolithic matrices taking into account a lag time.  The effective diffusion coefficient 
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was calculated and shown to be affected by the monomer type, degree of crosslinking, 
and presence of PEG tether. 
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Table 6.1 Tablet formulations prepared by dry compression. 
 
Component  wt % 
   
Multifunctional Polymer  50% 
Anhydrous Lactose  38% 
Theophylline  10% 
Cab-O-Sil  1.25%
Magnesium Stearate  0.75%
   




Table 6.2 Diffusional analysis of tablet matrices formulated according to Table 6.1 
composed of poly(acrylic acid) and crosslinked poly(acrylic acid) 
microparticles synthesized with varying levels of crosslinking agent. 
 Deff (x106  cm2/s) 
 pH = 1.2 pH = 6.8 
PAA 3.6 ± 0.21 4.2 ± 1.8 
x-PAA (0.20 mol % APE) 1.1 ± 0.04 0.74 ± 0.03 
x-PAA (0.43 mol % APE) 0.96 ± 0.76 0.81 ± 0.04 
x-PAA (0.75 mol % APE) 2.9 ± 0.47 3.9 ± 0.19 
Carbopol 971P-NF 1.20 ± 0.01 0.85 ± 0.01 
Carbopol 974P-NF 1.50 ± 0.15 1.60 ± 0.01 
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Table 6.3 Diffusional analysis of tablet matrices formulated according to Table 6.1 
composed of poly(methacrylic acid) and crosslinked poly(methacrylic acid) 
microparticles synthesized with varying levels of crosslinking agent. 
 
 Deff (x106  cm2/s) 
 pH = 1.2 pH = 6.8 
PMAA 0.62 ± 0.24 2.23 ± 0.02 
x-PMAA (0.43 mol % PETA) 1.24 ± 0.04 2.41 ± 0.02 
x-PMAA (0.75 mol % PETA) 1.72 ± 0.03 4.54 ± 0.08 
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Table 6.4 Diffusional analysis of tablet matrices formulated according to Table 6.1 
composed of crosslinked poly(acrylic acid) microparticles containing a 
poly(ethylene glycol) tether, with the tether concentration varied for each 
system below. 
 Deff (x106  cm2/s) 
 pH = 1.2 pH = 6.8 
P(AA-g-PEG), PEG-300, 90:10 1.35 ± 0.09 1.50 ± 0.05 
P(AA-g-PEG), PEG-300, 70:30 0.86 ± 0.02 1.01 ± 0.02 
P(AA-g-PEG), PEG-300, 50:50 1.02 ± 0.05 3.90 ± 0.56 
P(AA-g-PEG), PEG-2000, 70:30 1.18 ± 0.08 4.28 ± 0.20 
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Table 6.5 Diffusional analysis of tablet matrices formulated according to Table 6.1 
composed of crosslinked poly(methacrylic acid) microparticles containing a 
poly(ethylene glycol) tether, with the tether concentration varied for each 
system below. 
 Deff (x106  cm2/s) 
 pH = 1.2 pH = 6.8 
PMAA-g-PEG, PEG-1000, 80:20 0.69 ± 0.06 3.85 ± 0.20 
PMAA-g-PEG, PEG-1000, 70:30 0.69 ± 0.01 3.93 ± 0.14 
PMAA-g-PEG, PEG-1000, 50:50 0.18 ± 0.02 0.36 ± 0.04 
 






Figure 6.1 The reversible complexation/decomplexation behavior of complexation 
hydrogels.  The polymeric backbone consists of proton donating polyacids 
with proton accepting polymer tethers.  At low pH’s the polymers are 
participating in interpolymer complexation, effectively inhibiting diffusion 
out of the network.  At pH’s close and above the pKa of the polyacid, the 






Figure 6.2 Theophylline release from minitablet matrices containing poly(acrylic acid) 
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Figure 6.3 Theophylline release from minitablet matrices containing poly(acrylic 
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Figure 6.4 Theophylline release from minitablet matrices containing poly(methacrylic 
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Figure 6.5 Theophylline release from minitablet matrices containing 
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Figure 6.6 Theophylline release from minitablet matrices containing PEG-tethered 























Figure 6.7 Theophylline release from minitablet matrices containing PEG-tethered 





















Figure 6.8 Theophylline release from minitablet matrices containing PEG-tethered 




















Figure 6.9 Theophylline release from minitablet matrices containing PEG-tethered 



















Figure 6.10 Diffusional analysis of the release of the model drug theophylline from 





















Figure 6.11 Diffusional analysis of the release of the model drug theophylline from 
minitablet matrices containing crosslinked PAA (0.2 mol % APE) 






















Figure 6.12 Diffusional analysis of the release of the model drug theophylline from 
minitablet matrices containing crosslinked PAA (0.43 mol % APE) 




















Figure 6.13 Diffusional analysis of the release of the model drug theophylline from 
minitablet matrices containing crosslinked  PAA (0.75 mol % APE) 



















Figure 6.14 Diffusional analysis of the release of the model drug theophylline from 
minitablet matrices containing crosslinked  PAA (0.75 mol % APE) 






















Figure 6.15 Diffusional analysis of the release of the model drug theophylline from 
minitablet matrices containing Carbopol 971P-NF microparticles in 0.1 N 




















Figure 6.16 Diffusional analysis of the release of the model drug theophylline from 
minitablet matrices containing Carbopol 974P-NF microparticles in 0.1 N 






















Figure 6.17 Diffusional analysis of the release of the model drug theophylline from 






















Figure 6.18 Diffusional analysis of the release of the model drug theophylline from 
minitablet matrices containing crosslinked  PMAA (0.43 mol % PETA) 





















Figure 6.19 Diffusional analysis of the release of the model drug theophylline from 
minitablet matrices containing crosslinked  PMAA (0.75 mol % PETA) 




















Figure 6.20 Diffusional analysis of the release of the model drug theophylline from 
minitablet matrices containing P(AA-g-PEG), PEG-300, 90:10, 





















Figure 6.21 Diffusional analysis of the release of the model drug theophylline from 
minitablet matrices containing P(AA-g-PEG), PEG-300, 70:30, 





















Figure 6.22 Diffusional analysis of the release of the model drug theophylline from 
minitablet matrices containing P(AA-g-PEG), PEG-300, 50:50, 





















Figure 6.23 Diffusional analysis of the release of the model drug theophylline from 
minitablet matrices containing P(AA-g-PEG), PEG-2000, 70:30, 




















Figure 6.24 Diffusional analysis of the release of the model drug theophylline from 
minitablet matrices containing P(MAA-g-PEG), PEG-1000, 80:20, 




















Figure 6.24 Diffusional analysis of the release of the model drug theophylline from 
minitablet matrices containing P(MAA-g-PEG), PEG-1000, 70:30, 





















Figure 6.24 Diffusional analysis of the release of the model drug theophylline from 
minitablet matrices containing P(MAA-g-PEG), PEG-1000, 50:50, 


















Chapter 7:  Conclusions 
The field of bioadhesion is one that is rapidly evolving to aid in the development 
of materials that are capable of more effective drug delivery, enhanced disease treatment, 
and the prevention and understanding of disease transmission.  Biomimetic materials are 
quickly replacing those first-generation materials that relied heavily on the non-specific 
interactions they had with the natural tissue.  Drug delivery systems are employing 
nature’s method of covalent bond formation (thiomers) and specific interactions (lectins) 
through carefully designed surfaces (tethered surfaces).  Tissue engineering matrices are 
incorporating macromolecules that the body is capable of recognizing and utilizing in the 
rehabilitation of organ dysfunction and failure.  Some disease transmissions can be 
attributed to the ability of a microorganism or pathogen to adhere to an epithelial surface, 
and the fundamental understanding of this binding event could lead to more effective 
ways of prevention and treatment. 
Successfully engineered materials for bioadhesive applications, or the prevention 
of bioadhesion in some instances, will continue to incorporate biologically relevant 
moieties to aid in their effective use by the biological host.  Carbohydrates and their role 
in cell-cell and cell-matrix interactions are becoming increasingly important, and both the 
incorporation of carbohydrate structures and their binding molecules will be crucial for 
the success of biomedical devices. 
The synthesis and characterization of pH responsive hydrogels were evaluated in 
this work to understand their application in bioadhesive controlled release drug delivery 
systems.  The effect of the addition of a PEG tether on the dynamics of these materials 
was investigated.  Novel drug delivery systems were designed that incorporated these pH 
responsive mucoadhesive biomaterials. 
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In the first part of this thesis, the synthesis of pH responsive microparticles 
composed of either poly(acrylic acid) or poly(methacrylic acid) were investigated.  The 
structure-property relationships of these biomaterials were evaluated.  The amount of 
crosslinking agent was varied to examine its effect on the dynamics of the materials.   
Microparticles composed of (meth)acrylic acid were successfully prepared using a 
thermally-initiated free-radical precipitation polymerization in ethyl acetate.  Particle size 
was shown to be dependent on crosslinking and monomer.  Slight morphological 
differences were observed due to differing polymer growth at the surface of the primary 
particle.  Structural differences were observed and interpreted using FT-IR with only 
slight differences being observed due to the presence of the methyl group.  The glass 
transition behavior of the materials was significantly different with MAA-based materials 
exhibiting a much higher Tg.  The Tg was also heavily dependent on the amount of 
crosslinking present in the network.  Crosslinked PAA possesses a higher swelling ratio 
than crosslinked PMAA with both polymers exhibiting pH dependent swelling. 
In the second part of this thesis, the synthesis and characterization of materials 
containing a PEG tether were evaluated.  The precipitation synthesis technique and 
microparticle formation was elucidated.  The fundamental understanding of the behavior 
of tethered gel networks has implications in tissue engineering, adhesion, and drug 
delivery.  In this research, ionizable hydrogel networks containing a PEG tether were 
successfully synthesized using a thermally initiated free radical precipitation 
polymerization.  The effects of the PEG tether on the structure of the microparticles were 
evaluated.  The addition of the PEG was shown to cause disruption of the dimer 
formation of PAA.  Differential scanning calorimetry exhibited a concentration 
dependent decrease in the Tg of xerogels.  At low concentrations, the network exhibits a 
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heterogeneous behavior which is evident through a lowered ∆ Cp and the presence of two 
distinct Tg’s.   
The gel adhesion of a neutralized gel was shown to be dependent on the amount 
of PEG incorporated into the network, which in turn affected the viscosity of the gel.  
These materials possess interesting swelling properties which can be beneficial in the 
development of pH responsive drug delivery systems. 
In the final part of this thesis, novel minitablet drug delivery systems containing 
the pH responsive microparticles and a model drug were formulated.  The release of a 
model drug was shown to be dependent on the amount of crosslinking agent incorporated 
during microparticle synthesis with lower degrees of crosslinking being preferred for 
effective release characteristics.  The amount of PEG was shown to significantly alter the 
release behavior due to interpolymer complexation between the ether oxygens and the 
carboxylic acid groups.  The release behavior was modeled according to a simplified 
model for monolithic matrices taking into account a lag time.  The effective diffusion 
coefficient was calculated and shown to be affected by the monomer type, degree of 
crosslinking, and presence of PEG tether. 
To summarize, this work contributed to the understanding of the potential of 
developing multifunctional polymers and drug delivery systems capable of controlling 
diffusion and modulating adhesion.  The PEG tether was shown to be effective in 
enhancing the pH responsive nature of the systems.  Also, the adhesive effects of the 
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INTRODUCTION 
Biomaterials have received a considerable amount of attention over the last 30 
years as a means of treating diseases and easing suffering.  The focus of treatment is no 
longer a conventional pharmaceutical formulation but rather a combination of device-
integrated biomaterial and the necessary therapeutic treatment.  Biomaterials have found 
applications in approximately 8,000 various kinds of medical devices (1) which have 
been used in repairing skeletal systems, returning cardiovascular functionality, replacing 
organs, and repairing or returning senses (2). Even though biomaterials have had a 
pronounced impact in medical treatment, a need still exists to be able to design and 
develop better polymer, ceramic, and metal systems (3). 
Polymeric biomaterials originated as off-the-shelf materials that clinicians were 
able to use in solving a problem—for example, dialysis tubing was originally made of 
cellulose acetate, vascular grafts were fabricated from Dacron, and artificial hearts were 
molded from polyurethanes (2).  However, these materials did not possess the chemical, 
physical, and biological properties necessary to prevent further complications.  Recent 
advances in synthetic techniques have allowed these properties to be imparted on 
polymeric biomaterials which help to alleviate accompanying biocompatibility issues.  
Nanotechnology, as this chapter will describe, further adds to the ability of chemically 
tailoring polymeric materials to provide more opportunities for revolutionary 
breakthroughs in the science and technology associated with developing novel devices.  
Undoubtedly, nanoscale science and engineering has the potential to have a profound 
impact on medical science and technology which will lead to improved diagnostics and 
enhanced therapeutic methods (4). 
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For ceramics and metals, similar advancements through the use of 
nanotechnology can be envisioned. For example, over the past nine decades of 
administering bioimplants to humans, most synthetic prostheses consist of ceramic or 
metal particles and/or grain sizes with conventional dimensions (on the order of 1 to 104 
µm). But the lack of sufficient bonding of these synthetic implants to surrounding body 
tissues have, in recent years, led to the investigations of novel material formulations. One 
such classification of materials, nanophase ceramics and metals (or materials with 
constituent components less than 100 nm in at least one direction), can be used to 
synthesize implants with similar surface roughness to that of natural tissues. Natural 
tissues have numerous nanometer features available for cellular interactions since they 
are composed of many nanostructures (specifically, proteins). Several nanophase ceramic 
and metals biomedical implants are currently being investigated, and are likely to gain 
approvals for clinical use in the near future. 
One area in which nanophase polymers, ceramics, and metals are being heavily 
investigated involves orthopedic/dental applications and this is for good reason.  Since 
1990, the total number of hip replacements, which is the replacement of the femoral and 
hip bones, has been steadily increasing (5-11). In fact, the 152,000 total hip replacements 
in 2000 is a 33% increase from the number performed in 1990 and a little over half of the 
projected number of total hip replacements (272,000) by the year 2030 in the United 
States alone (5-8). However, in 1997, 12.8% of the total hip arthroplasties were simply 
due to revision surgeries of previously implanted failed hip replacements (5-8).  
The fact that such a high percentage of hip replacements performed every year are 
revision surgeries is not surprising when you consider the life expectancy of the implant 
versus that of the patient receiving the implant. Consistently, over 30% of those requiring 
total hip replacements have been below the age of 65 and even those at the age of 65 have 
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a life expectancy of 17.9 years (9-11). Females, which comprise a majority of those 
receiving total hip replacements, have a life expectancy of 19.2 years at the age of 65. 
Since the longevity of implants ranges only from about 12-15 years, even the majority of 
those that receive bone implants at the age of 65 will require at least one revision surgery 
before the end of their lives (9-11).  
For the dental community the story is not any better. Since dental implants may 
be necessary for the young and old alike, it is imperative that they are able to last for the 
duration of the patient’s life. Recent studies have found that dental implants which have 
been used in over 300,000 cases in the United States, have up to a 96% success rate 
(meaning that the implant was not mobile and was non-inflamed) after five years, 80% 
after ten, and less than 75% after 15 years (5-11).     
The above strongly suggests that the longevity of the current prostheses is a 
reoccurring problem for the orthopedic/dental community that has to be dealt with since 
current approaches clearly fail. Orthopedic implant failure can be due to numerous 
reasons including: poor initial bonding of the implant to juxtaposed bone, generation of 
wear debris that lodges between the implant and surrounding bone to cause bone cell 
death, and/or stress and strain imbalances between the implant and surrounding bone 
causing implant loosening and eventual failure (12). Although there are many reasons 
why implants fail, a central one is the lack of sufficient bone regeneration around the 
implant immediately after insertion (12). Shockingly, about a quarter of dental implant 
failures are attributed to incomplete healing of the implant to juxtaposed bone (for those 
that failed between three and six months) (5-11).  Importantly, this leads to eventual 
implant loosening and regions for possible wear debris to situate between the implant and 
surrounding bone further complicating bone loss (12-15). 
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Nanotechnology is playing an important role in decreasing this failure. This is 
because, in order to improve biomaterial performance and hence extend the lifetime of 
bone implants, it is essential to design surface characteristics that interface optimally with 
select proteins and subsequently with pertinent bone cell types. That is, immediately after 
implantation, proteins will adsorb from plasma to biomaterial surfaces to control cell 
attachment and eventual tissue regeneration (Figure 1) (16,17). Initial protein interactions 
that mediate cell function depend on many biomaterial properties including chemistry, 
charge, wettability, and topography (16,17). Of significant influence for protein 
interactions is surface roughness and energy (18-22), and this represents the promise of 
nanophase materials in bone implant applications.  
The critical factor for the merging of nanotechnology with medicine is the 
increasingly documented special, biologically-improved material properties of nanophase 
implants compared to conventional formulations of the same material chemistry. In this 
manner, this review paper will highlight a novel property of nanophase materials that 
makes them attractive for use as implants: increased tissue regeneration. Active works are 
focused in the domains of orthopedic, dental, bladder, neurological, vascular, cartilage, 
and cardiovascular applications. However, only orthopedic applications, which are the 
closest to clinical applications, will be emphasized here. This entry will briefly articulate 
the seeming revolutionary changes and the potential gains nanostructured materials can 
make for bone implant technology.  
NANOTECHNOLOGY IN BIOMATERIALS SCIENCE 
The emergence of micro- and nanoscale science and engineering has provided 
new avenues for engineering materials with macromolecular and even down to molecular 
scale precision, leading to diagnostic and therapeutic technologies that will revolutionize 
the way health care is administered.  Biomaterials have evolved from off-the-shelf 
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products (e.g. Dacron for vascular grafts) to materials that have been designed with 
molecular precision to exhibit the desired properties for a specific application, often 
mimicking biological systems (2,3) .  
 Controlling interactions at the level of natural building blocks, from proteins to 
cells, facilitates the novel exploration, manipulation, and application of living systems 
and biological phenomena. Nanostructured tissue scaffolds and biomaterials are being 
applied for improved tissue design, reconstruction, and reparative medicine (23-26). 
Nano- and microarrays have been established as the preferred method for carrying out 
genetic and other biological (e.g. drug discovery) analysis on a massive scale (27).  
Natural nanopores (28,29), and synthetic nanopores of tailored dimensions (30,31) are 
probing, characterizing, and sequencing biological macromolecules and have 
demonstrated the possibility to analyze the structure of individual macromolecules faster 
and cheaper (32).  Self-assembly is being applied to create new biomaterials with well-
ordered structures at the nanoscale such as nanofiber peptide and protein scaffolds (33).  
In addition, polymer networks with precisely engineered binding sites have been created 
via molecular imprinting, where functional monomers are pre-assembled with a target 
molecule and then the structure is locked with network formation (34). 
In medical diagnostics, the speed and precision with which a condition is detected 
directly impacts the prognosis of a patient.  Point-of-care (POC) diagnostic devices, 
which enable diagnostic testing (in-vivo or ex-vivo) at the site of care, can enhance 
patient outcomes by substantially abbreviate analysis times as a result of the intrinsic 
advantages of the miniature device and by eliminating the need for sample transport to an 
onsite or off-site laboratory for testing. The development of micro or miniaturized total 
analysis systems (µ-TAS), also referred to as lab-on-a-chip devices, has profoundly 
impacted the corresponding development of POC diagnostic devices. These µ-TAS 
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devices integrate microvalves, micropumps, micro-separations, microsensors, and other 
components to create miniature systems capable of analysis that typically requires an 
entire laboratory of instruments. Since introduced as a novel concept for chemical 
sensing devices (35), µ-TAS devices have been applied as innovative biological devices 
(36) and point-of-care diagnostic devices (37,38). With the further development of micro- 
and nanosensors, POC diagnostic devices will provide for improved medical 
management, leading eventually to self-regulated point-of-care diagnostic devices that 
intermittently or continuously monitor the biological molecule of interest and deliver 
therapeutic agents as required. 
Additionally, nanoscale science and engineering has accelerated the development 
of novel drug delivery systems and led to enhanced control over how a given 
pharmaceutical is administered, helping biological potential to be transformed into 
medical reality (39).  Micro- and nanoscale devices have been fabricated using integrated 
circuit processing techniques and have been demonstrated to allow for strict control over 
the temporal control of drug release.  Silicon microchips that can provide controlled 
release of single or multiple chemical substances on demand via electrochemical 
dissolution of the thin anode membranes covering microreservoirs have been created 
(40).  The advantages of this microdevice include that it has a simple release mechanism, 
very accurate dosing, ability to have complex release patterns, potential for local 
delivery, and possible biological drug stability enhancement by storing in a microvolume 
that can be precisely controlled. More recently, multi-pulse drug delivery from a 
resorbable polymeric microchip device was demonstrated (41).    
In particular, the development of polymer systems that are able to interact with 
their environment in an “intelligent” manner has led to novel materials and applications.  
These intelligent materials are attractive options as functional components in micro- and 
 155
nanodevices, due to the ease with which there recognition and actuation properties can be 
precisely tailored.  In this section of the book, neutral and intelligent polymers and  
networks based on environmentally responsive hydrogels and biomimetic polymer 
networks will be discussed for application as sensing/recognition elements in novel 
diagnostic devices, such as microsensors and microarrays, and therapeutic devices, for 
tailoring loading and release properties.  
In addition to advances in polymer nanotechnology for sensing and recognizing 
changes in microenvironments, advances have been made concerning tissue regeneration 
on ceramic and metallic nanomaterials. Broadly speaking, nanotechnology embraces a 
system whose core of materials is in the range of nanometers (10-9 m) (42-52). The 
application of nanomaterials for medical diagnosis, treatment of failing organ systems or 
prevention and cure of human diseases can generally be referred to as nanomedicine 
(51,52). The branch of nanomedicine devoted to the development of biodegradable or 
non-biodegradable prostheses fall within the purview of nano biomedical science and 
engineering (51,52).  Although various definitions are attached to the word 
“nanomaterial” by different experts, the commonly accepted concept refers nanomaterials 
as that material with the basic structural unit in the range 1-100 nm (nanostructured), 
crystalline solids with grain sizes 1-100 nm (nanocrystals), individual layer or multilayer 
surface coatings in the range 1-100 nm (nanocoatings), extremely fine powders with an 
average particle size in the range 1-100 nm (nanopowders) and, fibers with a diameter in 
the range 1-100 nm (nanofibers) (42,43). 
Since nature itself exists in the nanometer regime, especially tissues in the human 
body (53), it is clear that nanotechnology can play an integral role in tissue regeneration. 
Specifically, bone is composed of numerous nanostructures – like collagen and 
hydroxyapatite that, most importantly, provide a unique nanostructure for protein and 
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bone cell interactions in the body (Figure 2) (50). Although mimicking constituent 
components of bone is novel in itself, there are additional reasons to consider 
nanomaterials for tissue regeneration such as in orthopedic applications: their special 
surface properties compared to conventional (or micron constituent component 
structured) materials (47-50). For example, a nanomaterial has increased numbers of 
atoms at the surface, grain boundaries or material defects at the surface, surface area, and 
altered electron distributions compared to conventional materials (Figure 3) (50) in 
summary, nanophase material surfaces are more reactive than their conventional 
counterparts. In this light, it is clear that proteins which influence cell interactions that 
lead to tissue regeneration will be quite different on nanophase compared to conventional 
implant surfaces (Figure 1). 
Despite this, the evolution of tissue engineering has centered on the use of 
materials with non-biologically inspired micron surface features (55,56), mostly changing 
in chemistry or micron roughness but not degree of nanometer roughness (Figure 4). In 
this manner, it should not be surprising why the optimal tissue engineering material (in 
particular, to regenerate bone) has not been found. 
CURRENT RESEARCH EFFORTS TO IMPROVE BIOMEDICAL PERFORMANCE AT THE 
NANOSCALE 
Nanoscale materials currently being investigated for bone tissue engineering 
applications can be placed in the following categories: ceramics, metals, polymers, and 
composites thereof. Each type of material has distinct properties that can be advantageous 
for specific bone regrowth applications. For example, hydroxyapatite, a ceramic mineral 
present in bone (Figure 2), can also be made synthetically. Ceramics, however, are not 
mechanically tough enough to be used in bulk for large scale bone fractures, however, 
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they have found applications for a long time as bioactive coatings due to their ionic 
bonding mechanisms favorable for osteoblast (or bone-forming cells) function (57).  
Unlike ceramic materials, metals are not found in the body. However, due to their 
mechanical strength and relative inactivity with biological substances, metals 
(specifically, Ti, Ti6Al4V, and CoCrMo) have been the materials of choice for large bone 
fractures (55,56). Polymers exhibit unique properties (such as viscosity, malleability, 
moldability) and possess mechanical strength that is comparable to many soft (not hard) 
tissues in the body (54). To date, because of their excellent friction properties, polymers 
(like ultra high molecular weight polyethylene) have been primarily used as articulating 
components of orthopedic joint replacements (58). Additionally, some polymers 
(particularly the polyester family) can be resorbed or degraded in the body, which opens 
the window for controllable repair of damaged bone that is actively being investigated in 
tissue engineering circles. Lastly, composites of any or all of the above, can be 
synthesized to provide a wide range of material properties to increase bone implant 
performance (71); such ability to tailor composite properties to specific orthopedic 
applications makes them attractive.  
Due to the numerous materials currently being used and investigated in 
orthopedics, this review will cover select efforts to create nanoscale surfaces in all of 
these categories: ceramics, metals, polymers, and composites. Several current and 
potential materials that have shown promise in nanotechnology for bone biomedical 
applications, as well as needed future directions, will be emphasized.    
SOFT BIOMATERIALS 
Polymers are only one of the four major classes of biomaterials; however, 
polymeric biomaterials have a significant advantage over metals, ceramics and natural 
materials in the fact that they can be chemically synthesized or modified according to the 
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desired application.  Hydrogels, hydrophilic and cross-linked polymeric structures, have 
received considerable attention for use in biomedical applications due to the 
biocompatible nature of their physical properties (72-74).  Poly(hydroxyethyl 
methacrylate) (PHEMA, 75) is the most widely used hydrogel, and the crosslinked 
variant has been frequently used in soft contact lenses (76,77).  Hydrogels are also widely 
used in pharmaceutical applications especially for the oral delivery of therapeutic 
proteins (78).  This class of materials is also capable of responding to changes in the 
external pH (Figure 20), temperature, ionic strength, nature and composition of the 
swelling agent, enzymatic or chemical reaction, and electrical or magnetic stimuli (79).   
Much consideration must be given when designing a material for a specific 
application.  Certain properties of the material must be controlled so as to perform the 
necessary function and elicit the appropriate response.  These properties can be tailored to 
the specific need by carefully controlling structural characteristics, modifying the surface 
properties, and employing biomimesis in the material design.  Hydrogels are a desirable 
type of material for biomedical devices because these properties can be controlled during 
or after the chemical synthesis, providing a significant amount of flexibility to aid in 
need-specific design applications. 
Structural Characteristics 
The hydrogel networks are prepared via chemical cross-linking, 
photpolymerization, or irradiative cross-linking (80) with the behavior of the materials 
dependent on their equilibrium and dynamic swelling behavior in water.  Flory (81) was 
the first to develop the theory of the swelling behavior of cross-linked polymers based 
upon a Gaussian distribution of the polymer chains.  Various parameters have been 
employed to define the equilibrium-swelling behavior.  Q, the volume degree of swelling, 
is the ratio of the actual volume of a sample in the swollen state divided by its volume in 
 159
the dry state; whereas, q, the weight degree of swelling, is the ratio of the weight of the 
swollen sample to that of the dry sample  (74).  The basic structure of the hydrogel is 
described by the molecular weight between cross-links,  , and the crosslinking density,  , 
and can be calculated from Eq. 1 and 2 respectively.  The structural characteristics 
influence the diffusion coefficient of solutes through the network, optical properties, 
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These key properties of the hydrogel are typically determined during initial 
synthesis of the biomaterial and are representative of the bulk structure of the material.  
Advances in nanotechnology have afforded the ability to further refine the structure by 
molecularly engineering the hydrogel to impart a recognitive capacity.  Domains within 
the molecularly designed hydrogel are able to recognize specific molecules through 
highly select non-covalent interactions between the building blocks of both the hydrogel 
network and the recognizable molecule (82). 
Surface Properties 
In addition to the bulk structural characteristics of the biomaterial, the surface 
plays a key role in the ability of the material to function as designed.  A surface provides 
a low energy barrier to mobility, a high accessibility for reaction, enhanced reaction 
turnover rates, and ultimately allows for molecular recognition (83).  As the first 
biomaterials were developed (intraocular lenses, hip joint replacements, and blood-
contacting devices), the importance of the surface properties, protein-surface interaction, 
 160
and surface modification was evident to researchers (84,85).  Baier (86) introduced 
methods having the ability to determine the driving mechanisms behind bioreactions.  
Hoffman (87) demonstrated that materials could be engineered so as to provide the 
desired biological responses necessary for effective biomaterial functionality. 
In this light, poly(ethylene glycol) (PEG) has received considerable attention for 
its use at the biomaterial/host interface to prevent protein fouling (88-90).  Castner and 
Ratner (83) list other strategies in addition to PEG that have been employed in 
biomaterials to prevent protein adsorption.  However, possessing the ability to design 
surface properties has not been able to fully solve the issues associated with the 
biocompatibility of the material.  True biocompatibility will be achieved when absorbing 
proteins are able to maintain their conformation, eliminating the detrimental foreign body 
reaction to this newly formed unnatural layer of denatured proteins (83).  The surface of 
the material must be designed so as to provide components inherent to the natural wound 
healing process.  This is an important contribution nanotechnology can make to improve 
biomaterial performance. 
Biomimetics 
The design and development of biomaterials has primarily been focused on the 
biocompatibility of the device with its surroundings, overlooking the biomolecular 
interactions that occur.  The paradigm for biomaterial characterization has shifted from 
one focusing on broad design parameters to one that focuses on eliciting specific 
molecular responses from the physiological environment.  Biomimetic materials emulate 
nature and mimic biological architecture to elicit a desired cellular response (91,126).  
Because of their hydrophilic structure, hydrogels inherently possess the characteristics of 
natural tissue; however, these materials in device form are much larger than the 
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individual cells.  The major thrust of biomimesis is to design structures that have the 
ability to interact on a sub cellular basis. 
In designing biomaterials one must understand the mechanisms by which cells 
interact in order for efficient biological mimicking.  Three specific interactions that are 
crucial in material development include cell adhesion, morphogenic stimuli signaling and 
endocytosis (91); since all of these are events controlled at the nanoscale, biomimetics is 
a field critical in nanotechnology. 
Nanoscale Biopolymer Carriers 
Polymer nanoparticle and nanosphere carriers (Figure 17,18) are very attractive 
for biomedical and pharmaceutical applications, due to their unique and tailorable 
properties. In the case of polymer networks, the release profile can be precisely 
controlled through the design of its molecular structure, such as degree of crosslinking 
and ionic characteristics of the pendent functional groups (59,60). 
Polymer nanospheres have been molecularly designed to be responsive to the pH 
of their environment, enabling for the protection of fragile therapeutic peptides (Figure 
19) and proteins in the harsh, acidic stomach environment and then release in the more 
amiable environment of the upper small intestine (61-63).  In addition, nanoparticle 
carriers have been designed to have stealth properties, allowing extended residence time 
without being recognized by the immune system (64,65). In other efforts, synthetic 
delivery systems, including polymeric nanoparticles, have been developed for application 
in gene delivery (66,67).  By creating polymer drug delivery systems that are 
biodegradable, the need for removal of the system post-delivery is eliminated, since the 
polymer can be naturally resorbed by the body (68).  Also, a number of companies are 
reformulating insoluble drugs as nanoparticles and nanocrystals to control uptake through 
cellular membranes.  
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Microchips (Figure 21) have been created for the storage and then delivery of 
multiple drugs in a controlled manor. For instance, a solid-state silicon microchip that can 
provide controlled release of single or multiple chemical substances on demand was 
fabricated and demonstrated (40,69).  The release is achieved via electrochemical 
dissolution of the thin anode membranes covering the microreservoirs filled with 
chemicals in solid, liquid, or gel form.  The advantages of this microdevice include that it 
has a simple release mechanism, very accurate dosing, ability to have complex release 
patterns, potential for local delivery, and possible biological drug stability enhancement 
by storing in a microvolume that can be precisely controlled. Recently, multi-pulse drug 
delivery from a resorbable polymeric microchip device was demonstrated (70). 
The aforementioned microdevices demonstrate only a few examples of the wide 
variety of novel applications that exist for integration of micro- and nanofabrication 
technologies with drug delivery, revealing the immaturity of the field. These novel drug 
delivery devices can enable efficient delivery that was unattainable with conventional 
drug delivery techniques, resulting in the enhancement of the therapeutic activity of a 
drug.   
CERAMIC NANOMATERIALS 
Perhaps slightly more mature, is the application of nanophase ceramics in bone 
tissue engineering applications. The next series of sections will highlight the 
improvement in bone regeneration that can be obtained through the use of ceramic 
nanotechnology. 
Increased Osteoblast Functions 
The first report correlating increased bone cell function with decreased material 
grain or particulate size into the nanometer regime dates back to 1998 and involves 
ceramics (92).  Such reports described that in vitro osteoblast (bone-forming cell) 
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adhesion, proliferation, differentiation (as measured by intracellular and extracellular 
matrix protein synthesis such as alkaline phosphatase), and calcium deposition was 
enhanced on ceramics with particulate or grain sizes less than 100 nm (92-101). 
Specifically, this was first demonstrated for a wide range of ceramic chemistries 
including titania (Figure 5), alumina, and hydroxyapatite (94). For example, four, three, 
and two times the amount of calcium-mineral deposition was observed when osteoblasts 
were cultured for up to 28 days on nanophase compared to conventional alumina, titania, 
and hydroxyapatite, respectively (96). It is important to note that for each respective 
nanophase and conventional ceramic mentioned in these first reports, similar chemistry 
and material phase were studied (92-101). That is to say, only the degree of nanometer 
surface features were altered between respective nanophase and conventional alumina, 
titania, and hydroxyapatite. This is important since as previously discussed it is well 
known that alterations in surface chemistry will influence bone cell function (12,55-71), 
but this was the first time changes in the degree of nanometer roughness alone were 
reported to enhance bone cell responses (92). 
Although these studies provided preliminary evidence that osteoblast functions 
can be promoted on nanostructured compared to conventional materials regardless of 
ceramic chemistry, Elias et al. further described a study where the topography of 
compacted carbon nanometer fibers were transferred to poly-lactic-glycolic acid (PLGA) 
using well established silastic mold techniques (102). The same was done for compacts 
composed of conventional carbon fibers. The successful transfer of nanometer compared 
to micron surface features from the carbon nanometer compared to conventional fiber 
compacts, respectively, is illustrated in Figure 6 (102). Importantly, osteoblast adhesion 
increased on PLGA molds made from nanometer compared to conventional carbon fibers 
(102). Increased osteoblast functions were also observed on the starting materials of 
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nanometer compared to conventional carbon fiber compacts (102). In this manner, this 
study provided further evidence of the importance of nanometer surface features (and not 
chemistry) in promoting functions of bone-forming cells.  
Equally as interesting, a step-function increase in osteoblast performance has been 
reported at distinct ceramic grain sizes: specifically, at alumina and titania spherical grain 
sizes below 60 nm (94). This is intriguing since when creating alumina or titania 
ceramics with average grain sizes below 60 nm, a drastic increase in osteoblast function 
was observed compared to respective ceramics with grain sizes just 10 nm higher (i.e, 
those with average grain sizes of 70 nm) (94). This critical grain size for improving 
osteoblast function is also of paramount importance since numerous other special 
properties (such as mechanical, electrical, catalytic, etc.) of materials have been reported 
when grain size is specifically reduced to below 100 nm (42-50).  With this information, 
evidence has been provided to show for the first time that the ability of nanophase 
ceramics to promote bone cell function is indeed limited to grain sizes (or subsequent 
surface features) below 100 nm, specifically those below 60 nm (94). Thus, another novel 
size-dependent property of nanostructured ceramics has been elucidated by these studies. 
Although an exact explanation as to why greater bone regeneration is observed on 
smaller grain size ceramics into the nanometer regime is not known to date, it is believed 
that the importance of this specific grain size in improving osteoblast function is 
connected with interactions of vitronectin (a protein known to mediate osteoblast 
adhesion with linear dimensions remarkably similar to the critical grain size of 60 nm 
mentioned above) (95,100). Moreover, as previously mentioned, several studies have 
indicated that vitronectin and other proteins important for osteoblast adhesion are more 
well-spread and, thus, expose amino acid sequences to a greater extent when interacting 
with nanometer compared to conventional ceramics (95,100). It is also intriguing to note 
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that numerous investigators have confirmed that the minimum distance between protein 
ligands (such as Arginine-Glycine-Aspartic Acid or RGD) necessary for cell attachment 
and spreading is in the nanometer regime (specifically, from 10 to 440 nm depending on 
whether the study was completed with full proteins, protein fragments, or single RGD 
units) (103-108). Therefore, an underlying substrate surface that mediates protein 
spreading (as opposed to protein folding) to expose such ligands coupled with a 
nanometer surface roughness to further project such ligands to the cell, may promote cell 
adhesion due to this optimal ligand spacing.  
Increased Osteoclast Function 
In addition to studies highlighting enhanced osteoblast function on nanophase 
ceramics, increased functions of osteoclasts (bone-resorbing cells) have been reported on 
nanospherical compared to larger grain size alumina, titania, and hydroxyapatite (HA) 
(101). Specifically, osteoclast synthesis of tartrate-resistant acid phosphatase (TRAP) and 
subsequent formation of resorption pits was up to two times greater on nanophase 
compared conventional ceramics such as hydroxyapatite. Coordinated functions of 
osteoblasts and osteoclasts are imperative for the formation and maintenance of healthy 
new bone juxtaposed to an orthopedic implant (12).  Frequently, newly formed bone 
juxtaposed to implants is not remodeled by osteoclasts and thus becomes unhealthy or 
necrotic (57). At this time, the exact mechanism of greater functions of osteoclasts on 
nanophase ceramics is not known, but it may be tied to the well-documented increased 
solubility properties of nanophase compared to conventional materials (48). In other 
words, due to larger numbers of grain boundaries at the surface of smaller grain size 
materials, increased diffusion of chemicals (such as TRAP) may be occurring to 
subsequently result in the formation of more resorption pits.   
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Collectively, results of promoted functions of osteoblasts coupled with greater 
functions of osteoclasts imply increased formation and maintenance of healthy bone 
juxtaposed to an implant surface composed of nanophase ceramics. In fact, although not 
compared to conventional grain size apatite coated metals, some studies have indeed 
demonstrated increased new bone formation on metals coated with nanophase apatite 
(109). As shown in Figure 7, bone formation can be clearly seen on the surface of metals 
coated with nano apatite, whereas there is no indication of new bone formation on the 
underlying metal without the coating (109). Incidentally, coating metals with nanophase 
HA has been problematic (110). For example, due to their small grain size, techniques 
which use high temperatures (like plasma spray deposition) are not an option since they 
will result in HA grain growth into the micron regime (110). To circumvent such 
difficulties, some investigators have allowed nanophase HA to precipitate on metal 
surfaces; this can be time consuming and not very controllable (109). In contrast, others 
have developed novel techniques which use high pressure based processes that do not 
significantly create elevated temperatures to coat nanophase ceramics on metals so as to 
retain their bioactive properties (Figure 8) (111). 
Decreased Competitive Cell Functions 
Importantly, it has also been shown that competitive cells do not respond in the 
same manner to nanophase materials as osteoblasts and osteoclasts do (95,102,112). In 
fact, decreased functions of fibroblasts (cells that contribute to fibrous encapsulation and 
callus formation events that may lead to implant loosening and failure (12) and of 
endothelial cells (cells that line the vasculature of the body) have been observed on 
nanophase compared to conventional ceramics (95).  In fact, the ratio of osteoblast to 
fibroblast adhesion increased from 1:1 on conventional alumina to 3:1 on nanophase 
alumina (95).  
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Previously, such selectively in bone cell function on materials has only been 
observed through delicate surface chemistry (such as through the immobilization of 
peptide sequences such as Lys-Arg-Ser-Arg or KRSR) (113). It has been argued that 
immobilized delicate surface chemistries may be comprised once implanted due to 
macromolecular interactions that render such epitopes non-functional in vivo. For these 
reasons, it is important to note that studies demonstrating select enhanced osteoblast and 
osteoclast functions with decreased functions of competitive cells on nanophase materials 
have been conducted on surfaces that have not been chemically modified by the 
immobilization of proteins, amino acids, peptides, or other entities (95,102,112). Rather it 
is the unmodified, raw material surface that is specifically promoting bone cell functions. 
Fibroblast function was also investigated in the same study that was previously 
mentioned in which Elias et al. transferred the topography of compacted carbon 
nanometer compared to conventional fibers to PLGA using well-established silastic mold 
techniques (again please refer Figure 6) (95). Similar to the observed greater osteoblast 
adhesion already noted, decreased fibroblast adhesion was measured on PLGA molds 
synthesized from carbon nanometer compared to conventional fibers (95). Again, this 
was the same trend observed on the starting material of carbon nanometer compared to 
conventional fiber compacts (95). Thus, this study demonstrated the importance of a 
nanometer surface roughness (and not chemical composition of the material) in 
decreasing functions of fibroblasts that may lead to undesirable fibrous encapsulation and 
callus formation events inhibiting osseointegration of orthopedic implants with 
surrounding bone. 
Increased Osteoblast Functions on Nanofibrous Materials 
Recently, researchers have further modified nanophase ceramics to simulate not 
only the nanometer dimension but also the aspect ratio of proteins and hydroxyapatite 
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crystals found in the extracellular matrix of bone (112). For example, consolidated 
substrates formulated from nano-fibrous alumina (diameter: 2 nm, length > 50 nm; Figure 
9) increased osteoblast functions in comparison with similar alumina substrates 
formulated from the aforementioned nanospherical particles (112). Specifically, Price et 
al. determined a two-fold increase in osteoblast cell adhesion density on nanofiber versus 
conventional nanospherical alumina substrates, following only a two-hour culture (112). 
Greater subsequent functions leading to new bone synthesis has also been reported on 
nanofibrous compared to nano and conventional spherical alumina (112). Thus, perhaps 
not only is the nanometer grain size of components of bone important to mimic in 
materials, but the aspect ratio may also be key to simulate in synthetic materials to 
optimize bone cell response.  
Another classification of novel biologically-inspired nanofiber materials that have 
been investigated for orthopedic applications are self-assembled helical rosette nanotubes 
(114). These organic compounds are composed of guanine and cytosine DNA pairs that 
self assembled when added to water to form unique nanostructures (Figure 10). These 
nanotubes have been reported to be 1.1 nm wide and up to several millimeters wide 
(114). Compared to currently used titanium, recent studies have indicated that osteoblast 
function is increased on titanium coated with helical rosette nanotubes (Figure 10) (114). 
Although in these studies it has not been possible to separate the influence of nanometer 
dimensions from the effects of nanotube chemistry on cell functions, it is clear that these 
nanotubes are another category of novel nanostructured materials that can be used to 
promote bone formation. It is also intriguing to consider what role self-assembled 
nanofibers may play in orthopedics since bone itself is a self-assembled collection of 
nanofibers.   
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In this context is it important to mention that only nanophase materials can mimic 
the unique aspect ratio of hydroxyapatite and proteins found in the extracellular matrix of 
bone; it is not possible for micron sized materials to simulate the unique nanometer 
constituent components of bone. As previously mentioned, results concerning the 
importance of nanofibrous materials in promoting functions of osteoblasts have been 
reported for carbon and polymer molds of carbon nanofibers (Figure 6) (102). These 
findings consistently testify to the unprecedented ability to create nanomaterials to mimic 
the dimensions of components of physiological bone to promote new bone formation.  
METAL NANOMATERIALS 
Although much more work has been conducted on nanophase ceramics for 
orthopedic applications to date, several recent studies have focused on the analysis of 
bone regeneration on nanophase metals. Metals investigated to date include titanium, 
Ti6Al4V, and CoCrMo (115).  While many have attempted to create nanostructured 
surface features using chemical etchants (such as HNO3) on titanium, results concerning 
increased bone synthesis have been mixed (58). Moreover, through the use of chemical 
etchants it is unclear to what the cells may be responding – changes in chemistry or 
changes in topography. For this reason, as was done for the ceramics in this review, it is 
important to focus on studies that have attempted to minimize large differences in 
material chemistry and focus only on creating surfaces that alter in their degree of 
nanometer roughness. 
One such study by Ejiofor et al. utilized traditional powder metallurgy techniques 
without the use of heat to avoid changes in chemistry to fabricate different particle size 
groups of Ti, Ti6Al4V, and CoCrMo (Figure 11) (115). Increased osteoblast adhesion, 
proliferation, synthesis of extracellular matrix proteins (like alkaline phosphatase and 
collagen), and deposition of calcium containing mineral was observed on respective 
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nanophase compared conventional metals (115). This was the first study to demonstrate 
that the novel enhancements in bone regeneration previously seen in ceramics by 
decreasing grain size can be achieved in metals.  
Interestingly, when Ejiofor et al. examined spatial attachment of osteoblasts on 
the surfaces of nanophase metals, they observed directed osteoblast attachment at metal 
grain boundaries (Figure 12) (115). Because of this, the authors speculated that the 
increased osteoblast adhesion may be due to more grain boundaries at the surface of 
nanophase compared to conventional metals. As was the case with nanophase ceramics 
(95,100), it is plausible that protein adsorption and conformation at nanophase metal 
grain boundaries may be greatly altered compared to non-grain boundary areas and/or 
conventional grain boundaries; in this manner, protein interactions at grain boundaries 
may be key for osteoblast adhesion.  
POLYMERIC NANOMATERIALS 
For ceramics and metals, most studies conducted to date have created desirable 
nanometer surface features by decreasing the size of constituent components of the 
material: for example, a grain, particle, or fiber. However, due to the versatility of 
polymers, many additional techniques exist to create nanometer surface roughness values. 
In addition, polymers contribute even further to rehabilitating damaged tissue by possibly 
providing a degradable scaffold that dissolves within a controllable time while the native 
tissue reforms. Techniques utilized to fabricate nanometer features on polymers include 
e-beam lithography, polymer demixing, chemical etching, cast-mold techniques, and the 
use of spin-casting (115-123). For those that have been applied to bone regeneration, 
chemical etching followed by mold casting and polymer demixing techniques have 
received the most attention (116,117).  
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For chemical etching techniques, polymers investigated to date include poly-
lactic-co-glycolic acid (PLGA; Figure 13), polyurethane, and polycaprolactone (117,119-
121). The idea proposed by Kay et al. has been to treat acidic polymers with basic 
solutions (i.e., NaOH) and basic polymers with acidic solutions (i.e., HNO3) to create 
nanosurface features (117). While only on two-dimensional films, Kay et al. observed 
greater osteoblast adhesion on PLGA treated with increasing concentrations and exposure 
times of NaOH. As expected, data was also provided indicating larger degrees of 
nanometer surface roughness with increased concentrations and exposure times of NaOH 
on PLGA. Park et al. took this one step further and fabricated three-dimensional tissue 
engineering scaffolds by NaOH treatment of PLGA (119). When comparing osteoblast 
functions on such scaffolds, even though similar porosity properties existed between non-
treated and NaOH treated PLGA (since similar amounts and sizes of NaCl crystals were 
used to create the pores through salt-leaching techniques), greater numbers of osteoblasts 
were counted on and in NaOH treated PLGA (119). Unfortunately, due to these 
fabrication techniques, it is unclear whether the altered PLGA chemistry or nano-etched 
surface promoted osteoblast adhesion; however, in light of the previous studies 
mentioned in this review, the authors of that study suggested the nanometer surface 
roughness of the NaOH-treated PLGA played an important role (119). 
Studies have also been conducted on cell responses to polymers with changes in 
nanometer surface roughness without changes in chemistry. Specifically, Li et al. utilized 
polymer demixing techniques to create well-controlled nanometer islands of polystyrene 
and polybromo-styrene (122). Although osteoblast functions have not been tested on 
these constructs to date, fibroblast morphology was significantly influenced by 
incremental nanometer changes in polymer island dimensions (Figure 14). Again, this 
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study points to the unprecedented control that can be gained over cell functions by 
synthesizing materials to have nanometer surface features.  
Although not related to orthopedic applications, vascular and bladder cell 
responses have also been promoted by altering the topography of polymeric materials in 
the nanometer regime (117,119,121,123).  In these studies, chondrocytes (117), bladder 
(121), and vascular smooth muscle cell (120) adhesion and proliferation were greater on 
two-dimensional nanometer surfaces of biodegradable polymers such as PLGA, 
polyurethane, and polycaprolactone; similar trends have recently been reported on three-
dimensional PLGA scaffolds (123).  
COMPOSITE NANOMATERIALS 
Due to the previous information of increased osteoblast function on ceramics and 
polymers, investigators have also determined bone cell function on nanophase ceramic 
polymer composites. Specifically, studies conducted to date show promoted osteoblast 
responses on composites of PLGA combined separately with nanophase alumina, titania, 
and hydroxyapatite (30:70 wt.% PLGA:ceramic) (117,124). For example, up to three 
times more osteoblasts adhered to PLGA when it contained nanophase compared to 
conventional titania particles (117). Since similar porosity (both % and diameters) existed 
between PLGA with conventional compared to nanophase titania, another novel property 
of nanophase ceramic composites was elucidated in this study: increased osteoblast 
functions. This is in addition to numerous reports in the literature highlighting greater 
toughness of nanophase compared to conventional ceramic:polymer composites (44-46). 
Moreover, promoted responses of osteoblasts have also been reported when 
carbon nanofibers were incorporated into polymer composites; specifically, three times 
the number of osteoblasts adhered on polyurethane (PU) with increasing weight 
percentages of nanometer not conventional dimension carbon fibers (125). As mentioned, 
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reports in the literature have demonstrated higher osteoblast adhesion on carbon 
nanofibers in comparison with conventional carbon fibers (or titanium (ASTM F-67, 
Grade 2) (125), but this study demonstrated greater osteoblast adhesion with only a 2 wt. 
% increase of carbon nanofibers (CN) in the PU matrix.  Up to three and four times the 
number of osteoblasts that adhered on the 100:0 PU:CN wt. %, adhered on the 90:10 and 
the 75:25 PU:CN wt.% composites, respectively (125). This exemplifies the 
unprecedented ability of nanophase materials to increase functions of bone cells whether 
used alone or in polymer composite form.  
AREAS OF APPLICATION 
While there has already been some effort spent on incorporating nanotechnology 
into orthopedic applications, it is clear that this is only the beginning for the incorporation 
of nanotechnology into biology; below some additional avenues are highlighted. 
Drug Delivery 
Polymers have found a significant role in the development of novel drug delivery 
systems.  Biomaterials for mucoadhesive drug delivery applications have been improved 
through the addition of poly(ethylene glycol) as an adhesion promoter (127-130).  
Additionally, smart hydrogel drug carriers have been molecularly designed to safely carry 
proteins and peptides to the duodenum region, avoiding the harsh, acidic conditions of 
the stomach and the proteolytic enzymes present along the gastrointestinal tract (131-
133).  Drug delivery systems composed degradable polymers such as polyanhydrides 
(134-137), polyorthoesters (138,139), and poly(lactic-co-glycolic acid) (PLGA,140,141) 
have been implemented in chemically-controlled drug delivery. 
Lu and Chen (142) have highlighted recent developments in the nano-fabrication 
of biodegradable drug delivery systems, and Leoni and Desai (143) have offered a review 
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of the abilities to create nanoporous structures containing an optimal pore size and 
distribution.  Nanoporous structures (144) have the ability to allow mass transport of 
desirable compounds but limit those that are undesirable.  An example given in the 
aforementioned review is the nanoporous encapsulation of pancreatic islet cells.  The 
controlled pore size could allow certain molecules’ transport such as glucose but 
significantly hinder the diffusion of molecules responsible for causing immune response 
mediate device failure such as immunoglobulin G  and M molecules (IgG, IgM). 
Nano drug delivery systems are quickly evolving in their ability to integrate 
biologically complex components into a functional nanodevice.  Lee et. al. (145) offers 
the bacmid process as an object-oriented approach for designing novel nanosystems and 
outlines the possibility of using this type of design process for effective delivery of 
vaccines.  Santini et. al. (40) have demonstrated the ability to deliver nanoliter quantities 
of therapeutics on demand from an array of sealed reservoirs.  Drug discovery and 
delivery are becoming sciences that encompass skills developed in nanotechnology, 
microtechnology, and biology to effectively design systems more capable of achieving 
efficient and effective therapeutic treatments (147). 
Much effort has been dedicated to engineering naoparticulate drug delivery 
systems (148,149).  Surface modification allows the specific targeting of the particles and 
enhances their ability to interact with certain types of cells (150).  Size plays a key role in 
the ability of particles to participate in intracellular uptake, and biodegradable 
nanoparticles can be used as sustained release delivery systems once inside the cytoplasm 
(151). 
Tissue Engineering 
Tissue engineering strives to create living tissue and organs through the use of 
synthetic, hybrid, or natural materials that have been designed or fabricated in a way to 
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elicit a desirable cellular response from the scaffold (152).  The major thrust of 
developing materials for tissue engineering is providing the cells an environment in 
which they can continue their normal functionality.  Biodegradable and resorbable 
materials are favorable due to the lack of necessity of a material structure to be present 
once the matrix has been formed.  Poly(lactic acid), poly(glycolic acid), and their 
copolymers (PLGA) were first utilized in the development of  biodegradable materials for 
tissue engineering applications, followed by other types of materials that include 
polyurethanes (153), polyanhydrides (154,155), and, more recently, poly(ether-
anhydrides) (156). 
This chapter already provided some nanotechnology-based examples of tissue 
engineering advances in orthopedics. In addition, Tsang and Bhatia (157) offer an 
extensive review into the fabrication techniques developed to aid in the development of 
novel tissue scaffolds.  Significant advances in fabrication using heat, light, adhesives, 
and molding are elaborated upon.  The use of cells to self-assemble native cellular 
matrices and cell/scaffold hybrids are also highlighted.  Biomimetic materials are actively 
being pursued as integral components of novel tissue engineering biomaterials (158,159).  
Various techniques are being employed to take advantage of the ability to modify the 
surface of tissue engineering materials, with RGD modification receiving the most 
attention (160). 
Synthetic hydrogels have traditionally been employed in the development of 
tissue engineering scaffolds due to their high biocompatibility, hydrophilicity, and tissue-
like properties.  The molecular design of these materials affords the engineer to impart 
certain physical properties into the device to obtain the necessary physiological response.  
Poly(lactic acid)-g-poly(vinyl alchol) (PLA-g-PVA) have been developed into heart 
valves (161), and PVA/poly(vinyl pyrrolidone) (PVA/PVP) blends have been proposed 
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for nucleus pulposus replacement (162).  Natural materials that have been developed for 
tissue engineering applications include collagen, hyaluronic acid, alginate, and chitosan 
(163). 
Hybrid materials are being utilized to take advantage of the ability to synthesize 
polymeric materials with specific properties combined with a bioactive entity that helps 
elicit a particular biological response.  PVA, a synthetic polymer, and chondroitin sulfate, 
a biological polymer, have been used to synthesize hydrogels that promote 
chondrogenesis (164).  Mixtures of peptides and synthetic polymers are combined in 
order to mimic extracellular matrix (ECM) proteins to enable natural wound healing and 
reduce the formation of fibrous encapsulation.  RGD has been used frequently to impart 
these properties into a biomaterial (160). 
Biological Micro-Electro-Mechanical Systems (BioMEMS) 
Most research focusing on BioMEMS is for their use in diagnostic devices and for 
the detection of DNA, viruses, proteins, and other biologically derived molecules (165).  
Nanoscale BioMEMS could allow for the real time detection and analysis of signaling 
pathways, which would further our knowledge and understanding of the basic 
mechanisms and functions of the cell.  While nanoscale BioMEMS is at its infancy, it is 
clear that nanotechnology will play an important role in its development.  
CONSIDERATIONS AND FUTURE DIRECTIONS 
Although preliminary attempts to incorporate nanotechnology into biomedical 
applications seem promising, numerous urgent questions still remain about this new field. 
First and foremost, the safety of nanoparticles once in the human body remains largely 
unanswered both from a manufacturing point of view and when used in full or as a 
components of an implantable device. Since such particles are smaller than many pores of 
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biological tissues, it is clear that this information will have to be obtained before further 
consideration of implantable nanomaterials is undertaken. Such nanoparticles can easily 
become dislodged from implants during surgical implantation or from fragmentation of 
articulating components of a joint prosthetic composed of nanophase materials. Although 
preliminary in vitro studies highlight a less adverse influence of nanometer compared to 
micron particulate wear debris on bone cell viability (166,167), many more experiments 
are needed especially in vivo to evaluate their efficacy.  
Specifically for orthopedic applications, additional questions remain. For 
example, once exact optimal nanometer surface features are elucidated for increasing 
bone regeneration, inexpensive tools that can be used in industry will be required. In this 
context, if the only nanofabrication devices that can be used to synthesize desirable 
nanometer surface features for bone regeneration are e-beam lithography or other equally 
expensive techniques, industry may not participate in this boom of nanotechnology at the 
intersection of tissue engineering. Inexpensive, but effective, nanometer synthesis 
techniques must continually be a focus of many investigators.  
Still, the direction of the nanotechnology should be and is geared toward dealing 
with these issues. For example, according to the U.S. government’s research agenda, the 
current and future broad interests in nano biomedical activity can be categorized in three 
broad related fronts (51,52): 
(i) development of pharmaceuticals for inside-the-body applications – such as 
drugs for anticancer and gene therapy; 
(ii) development of diagnostic sensors and lab-on-a-chip techniques for 
outside-the-body applications – such as biosensors to identify bacteriological infections 
in biowarfare; and  
(iii) development of prostheses and implants for inside-the-body uses.  
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Whereas the European governments emphasize commercial applications in all 
three fronts above according to Marsch (52), the U.S. government tends to gear towards 
fundamental research on biomedical implants and biodefense, leaving commercial 
applications to industry. Both classifications identify nanophase biomedical implants as 
potential interests. The biological and biomimetic nanostructures to be used as an 
orthopedic implant involve some sort of an assembly in which smaller materials later on 
assume the shape of a body part, such as hipbone. These final biomimetic, bulk 
nanostructures can start with a predefined nanochemical (like an array of large reactive 
molecules attached to a surface) or nanophysical (like a small crystal) structure. It is 
believed that by using these fundamental nanostructured building blocks as seed 
molecules or crystals, a larger bulk material will self-assemble or keep growing by itself.  
In summary, it is now believed that significant evidence exists that highlights the 
promise nanotechnology has for biological applications, particularly in the bone arena. 
Clearly, nanomaterials as mentioned here are at their infancy and require much more 
testing before their full potential can be realized. However, even if nanophase materials 
never make it to the marketplace due to safety concerns, we have already learned much 
about how cells interact with surfaces through their application in the orthopedic 
environment.    
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Figure A.1:  Cell recognition of biomaterial surfaces controlled by initial protein 
interactions. Initial protein interactions can influence cell adhesion and, 
thus, degree of bone tissue formation on biomaterials. Changing material 
properties will alter protein interactions and influence subsequent cell 
function. (Adapted and redrawn from Schakenraad, J.M., in Biomaterials 
Science: An Introduction to Materials in Medicine, Ratner, B.D., Hoffman, 
A.S., Schoen, F.S., and Lemmons, J.E., Eds., Academic Press, New York, 
NY, 1996, pp. 133-140. With permission.) 
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Figure A.2:  Nanocomponents of bone provide a high degree of nanostructured surface 
roughness for bone cells. (Adapted and redrawn from Cowin, R., Handbook 



















Figure A.3:  Special surface properties of nanophase materials. (a) Higher number of 
atoms at the surface for nanophase compared to conventional materials. (b) 
Nanophase materials have higher surface areas, possess greater numbers of 
material defects at the surface, and altered electron delocalization. Such 
special properties will influence protein interactions for controlling cell 
functions. (Adapted and redrawn from Klabunde, K.J. et al., J. Phys. Chem., 
100, 12141, 1996. With permission.) 
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Figure A.4:  Conventional grain size of currently used orthopedic implants. Bar = 10 and 
1 micron for the left and right micrograph, respectively.  
Ti (Medical Grade 2) at a 
magnification of 100X 
Ti (Medical Grade 2) at a 




















Figure A.5:  (a) Conventional and (b) nanophase titania. One of the first studies 
correlating increased osteoblast function with decreasing ceramic grain size 
was done on titania as pictured here. (From Webster, T.J., Siegel, R.W., and 














































Figure A.6:  Poly-lactic-glycolic acid (PLGA) molds of conventional and nanophase 
carbon fiber compacts. To highlight the importance of nanometer surface 
roughness regardless of substrate chemistry, studies have shown increased 
functions of osteoblasts on PLGA molds of nanophase compared to 
conventional carbon compacts. Studies have also shown increased functions 
of osteoblasts on compacts composed of nanometer compared to 
conventional carbon fibers. Bar = 1 micron. (From Elias, K.L., Price, R.L., 
and Webster, T.J., Biomaterials, 23, 3279-3287, 2002. With permission.) 





























Figure A.7: Increased in vivo bone regeneration on titanium coated with nanophase 
apatite. Scanning electron micrograph of nanometer dimensioned apatite 
(specifically, between 100 – 200 nm in size) is depicted in (a). Increased 
bone regeneration in titanium cages when coated with nano-apatite is 
depicted in (b). (From Li, P., J. Biomed. Mat. Res 66, 79-85, 2003. With 
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Figure A.8:  Nanophase hydroxyapatite coated on titanium. Due to elevated 
temperatures, traditional coating techniques, like plasma spray deposition, 
cannot be used to coat metals with nanophase ceramics. This process 
developed by Spire Biomedical (Bedford, MA) uses high pressure at low 

























Figure A.9:  Transmission electron microscope image of alumina nanofibers. Compared 
to spherical conventional alumina, increased functions of osteoblasts have 
been reported on nanophase fibrous alumina. Scale bar = 10 nm. (From 
Price, R.L. et al., J. Biomed. Mat. Res, 67 (4), 1284, 2003. With 
permission.) 






















Figure A.10:  Helical rosette nanotubes. Drawing of the cross-sectional (left) and 
longitudinal (right) view of self-assembled helical rosette nanotubes is 
depicted in (a) while helical rosette nantoubes coated on titanium is depicted 
in (b). Note the nanophase dimension of these organic tubes. Increased 
osteoblast function has been observed on helical rosette nanotubes coated on 



















Figure A.11:  Scanning electron micrographs of nanophase metals. Increased functions 
of osteoblasts have been observed on nanophase compared to conventional 
c.p. Ti, Ti6Al4V, and CoCrMo. Scale bar = 1 micron for nanophase 
Ti/Ti6Al4V and 10 microns for conventional Ti/Ti6Al4V. Scale bar = 10 
microns for nanophase and conventional CoCrMo. (From Ejiofor, J.U. and 




























Figure A.12:  Scanning electron micrographs of adherent osteoblasts on nanophase c.p. 
Ti. Directed osteoblast adhesion on nanophase metal grain boundaries has 
been reported. Scale bar = 100 microns for top and 10 microns for bottom. 
Adhesion time = 30 minutes. (From Ejiofor, J.U. and Webster, T.J., ASM 





















Figure A.13:  Scanning electron micrographs of conventional and nanophase PLGA 
scaffolds. Increased osteoblast functions have been demonstrated on 
nanophase PLGA scaffolds.  Scale bar = 10 microns. (From Park, G.E., 
Park, K., Webster, T.J., Biomaterials, in press, 2004. With permission.) 
a) Conventional PLGA b) Nano-structured PLGA 











Figure A.14:  Polymer nanoislands created by demixing polystyrene and polybromo-
styrene. Altered cell functions have been observed on polymer nanoislands 
compared to conventional polymer topographies. (a) through (d) represents 
increased magnification. (From Li, W.-J. et al., J. Biomed. Mat. Res, 60, 

























Figure A.15:  Scanning electron micrographs of poly-lactic-glycolic acid (PLGA): 
titania composites. Increased osteoblast function has been observed on 
polymer composites containing nanophase compared to conventional 
ceramics. Scale bar = 10 microns. (From Smith, T.A. and Webster, T.J., J. 















          






    
 
          
 
 










        
    (e) 0:100 (PU:CN wt. %)     
Figure A.16:   Scanning electron micrographs of poly-ether-urethane (PU): carbon 
nanofibers (wt.%) composites. Increased functions of osteoblasts have been 
observed on polymer composites containing carbon nanofibers. Scale bar = 





Figure A.17:   TEM image of P(MAA-g-EG) nanospheres prepared from a MAA/EG 
molar feed ratio of 1:1.  The P(MAA-g-EG) nanospheres were stained with 










Figure A.18:   TEM image of P(MAA-g-EG) nanospheres prepared from a MAA/EG 
molar feed ratio of 1:1.  The P(MAA-g-EG) nanospheres were stained with 




Figure A.19:   Optical section of a Caco-2 cell monolayer grown on microporous 
Transwell® plates obtained with a confocal microscope.  FITC-labeled 
insulin (green) was added to the apical chamber of the cell monolayer in the 
presence of poly(methacrylic acid-grafted-ethylene glycol) microparticles 





Figure A.20:    Network structural changes due to variations on environmental pH.   
Higher pHs disrupt the interpolymer complexes and ionic moieties deprotonize leading to 
extensive swelling (left).  As pH is decreased, interactions between the tethered grafts 





Figure A.21:   In (A) 3D projection a micropatterned square array of a biomimetic 
polymer network based on a crosslinked polyacrylamide obtained utilizing a 
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